General Child Neurology
Acute cerebellar ataxia in children
Oct. 29, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Cerebral palsy …
- Updated 06.05.2024
- Released 02.07.1994
- Expires For CME 06.05.2027
Cerebral palsy
Introduction
Overview
Cerebral palsy describes a group of genetic and acquired childhood neurologic disorders characterized by abnormalities in tone, posture, and movement as a result of early injury to the developing brain. Cerebral palsy is often associated with language and intellectual disability, social impairment, epilepsy, other organ system involvement, and functional limitations. An appropriate diagnostic assessment and resource environment is important to ensure proper treatment and management. Neuroprotective strategies, including therapeutic hypothermia and adjuvant therapy, have been shown to reduce morbidity and mortality caused by hypoxic-ischemic encephalopathy, including cerebral palsy. In this article, the author discusses the many aspects of diagnosing and managing cerebral palsy.
Key points
|
• Cerebral palsy describes a group of nonprogressive genetic and acquired childhood neurologic disorders characterized by abnormalities in tone, posture, and movement as a result of injury to the developing brain. | |
|
• Although characterized by their motor dysfunction, children with cerebral palsy frequently have other associated impairments, which include language delay, seizures, strabismus, dysphagia, orthopedic deformities, and cognitive problems. | |
|
• Advances in neuroimaging and genetics promise to further the understanding of the pathogenesis and pathophysiology of cerebral palsy. | |
|
• Effective management of cerebral palsy requires a team with medical and rehabilitative specialists to provide careful, ongoing neurodiagnostic evaluation and rehabilitation to maximize functional capabilities. | |
|
• Neuroprotective strategies, chiefly therapeutic hypothermia, have demonstrated decreased death and disability related to cerebral palsy. |
Historical note and terminology
Cerebral palsy describes a group of nonprogressive genetic and acquired childhood neurologic disorders characterized by abnormalities in tone, posture, and movement as a result of injury to the developing brain (147; 87; 20).
Debates surrounding the nomenclature, definition, and etiology of cerebral palsy continue. In the mid-1800s, Sir William Little proposed that cerebral palsy was related to difficult childbirth (164). In recent decades, this view has had significant medical and legal implications (187). In the late 1800s, Freud wrote, "Difficult birth, in certain cases, is merely a symptom of deeper effects that influence the development of the fetus" (81). This view suggested that cerebral palsy had a prenatal onset. The late 19th century brought further insight as Sir William Osler published his lectures, The Cerebral Palsies of Children, classifying the disorder by neuroanatomy, etiology, and extremity involvement (202).
The Collaborative Perinatal Project, a landmark American maternal and child health epidemiologic research study, demonstrated that the events of labor and delivery are not major contributors to the occurrence of cerebral palsy or most other neurodevelopmental disorders. Rather, most of these conditions originated before labor begins (192). Prenatal factors have emerged as the chief determinants of risk for cerebral palsy (29).
Clinical manifestations
Presentation and course
Clinical assessment allows classification by neurologic findings and topographical location. Although a number of classification systems exist (211; 281), categorization into specific phenotypes based on tone and limb involvement (Table 1) is of clinical benefit (116). Classification into a specific group may provide benefit when investigating etiology, determining medical and rehabilitative treatment, and determining recurrence risk. One should note, however, that (1) some individuals have signs of spasticity, rigidity, and dystonia and are often classified as “mixed” cerebral palsy, and (2) the motor manifestations of cerebral palsy may change over time (235).
Table 1. Classification of Cerebral Palsy Syndromes
|
Bilateral spasticity | |
|
• Spastic diplegia | |
|
Unilateral spasticity | |
|
• Spastic hemiplegia | |
|
Extrapyramidal (dyskinetic) | |
|
• Bradykinesia | |
|
Hypotonia and ataxia | |
Bilateral spasticity
Spastic diplegia. Spastic diplegia is a clinical syndrome with spasticity greater in legs than arms, seen most commonly in children born prematurely. Associated findings may include strabismus, orthopedic deformities, seizures, oromotor dysfunction, and disorders of cognitive function. It is primarily a disorder of developing white matter and is nearly always associated with neuropathological and neuroimaging findings of periventricular leukomalacia. As premature infants usually receive careful developmental follow-up after discharge from the neonatal intensive care unit, those with spastic diplegia are often identified during the first 6 to 12 months of life with signs of delayed motor development.
Spastic quadriplegia. Spastic quadriplegia represents bilateral spasticity affecting all extremities, with significant limitations in both mobility and hand use. Affected individuals commonly require a wheelchair for mobility. Associated deficits may be more severe, including intellectual disability, communication disorders, seizures, orthopedic deformities, including scoliosis and hip dislocation, and visual impairment. Spastic quadriplegia is the result of a broader range of pathological insults than spastic diplegia, including genetic and developmental brain malformations, severe periventricular leukomalacia, pre- and postnatal infections, asphyxia, and nonaccidental trauma. As with other cerebral palsy syndromes, low birth weight, prematurity, and complicated neonatal course are important risk factors. Delayed motor development in the first year is usually more prominent than in spastic diplegia.
Unilateral spasticity
Spastic hemiplegia. Spastic hemiplegia represents unilateral spasticity, often with recognizable etiologies. Independent ambulation and normal intelligence are commonly seen. There is an increased risk of seizures, growth asymmetry, and sensory impairment of the hemiplegic side.
Extrapyramidal (dyskinetic)
In children with extrapyramidal syndromes, clinical involvement is characteristically greater in the arms than legs. Extrapyramidal syndromes are often associated with a marked reduction in speech production, but the child may have relatively preserved intelligence. Close clinical observation and examination facilitate categorization in the below groups.
Bradykinesia. This refers to a slowing of movement, with a paucity of facial movements. On examination, there may be findings of hypertonic rigidity on passive limb movement.
Dystonia. This may be variably considered as twisting, repetitive movements with abnormal postures or as the production of one pattern of muscle activation when another is intended (239). At rest, muscle tone may be normal, with dystonic hypertonicity on volitional activity.
Choreoathetosis. This pattern of hyperkinetic movements may be seen individually as chorea (rapid, irregular, uncontrolled movements of the distal extremities), as athetosis (slower, writhing movements), or in combination.
Hemiballismus. Hemiballismus refers to wild, uncontrolled movements of the extremities. This may be incapacitating for day-to-day activities and a source of great embarrassment.
Hypotonia and ataxia
Less commonly, children present with hypotonia or ataxia, or both, with delayed motor milestones (66). These patients are distinguished by the preservation of strength and reflexes, suggesting a disorder of upper motor neurons. This is a heterogeneous group of disorders, including recognized and presumptive static genetic or genetic-metabolic disorders, such as mitochondrial encephalomyopathies (92), Angelman syndrome, Prader-Willi (268), carbohydrate glycoprotein syndromes (100), childhood spinocerebellar atrophies (169), and chromosomal deletions and rearrangements.
Associated impairments
Although characterized by their motor dysfunction, children with cerebral palsy frequently have other associated impairments (45; 247). Associated problems include language delay, seizures, strabismus, dysphagia, orthopedic deformities, and cognitive problems (45). Up to half of patients develop seizures, which commonly have their onset in the first years of life (03; 272). The incidence is greater in spastic quadriplegia and hemiplegia and lowest in mild spastic diplegia. About half of children with cerebral palsy have intellectual disability that can range from mild to severe. Intellectual disability is often closely associated with the presence of seizures, and patients with multiple seizure types are more likely to be severely delayed. Prolonged fixed primitive and postural reflexes are frequently mistaken for seizures. Impairments in hearing, vision, and speech are experienced in 15% to 20% of children with cerebral palsy. Abnormal speech and language may result from hearing loss, brain-based primary language problems, poor integration of motor mechanisms of the oropharynx, or poor coordination of breathing patterns.
Additional impairments include difficulties with swallowing and feeding, impaired growth, dental problems, respiratory disease, and emotional disorders. Swallowing and feeding disorders can develop with secondary esophagitis or aspiration (48; 227). Growth may be slow as a result of inadequate caloric intake, recurrent vomiting with aspiration secondary to gastroesophageal reflux, and pseudobulbar palsy.
Dental disease and chronic respiratory disease are both common. Respiratory problems can develop from severe reflux, palatopharyngeal dyscoordination, chest deformity, and poor coordination of respiratory muscles (125). Enuresis, frequency, urgency, and stress incontinence also occur in many children. These are related to neurogenic dysfunction, poor cognition and communication skills, limited mobility, and the expectations of caregivers (31).
Children with cerebral palsy may experience limitations in activities of daily living that contribute to behavioral and emotional difficulties (253; 21; 138). Problems in these areas should be promptly addressed by appropriate specialists to promote resolution and long-term success both socially and vocationally.
Criteria for diagnosis
Depending on severity, the diagnosis of cerebral palsy may be established between 1 and 2 years of age, although in children with milder phenotypes, it is often made after the age of 2 years. Normal motor development in infancy progresses from reflex-driven activity to adaptive postural reflexes to volitional activities. In one sense, cerebral palsy represents the persistence of reflex-driven activity, with the lack of emergence of cortical control. Many clinicians defer a diagnosis of cerebral palsy during early infancy unless profound motor delay is seen. Reasons for caution with regard to early diagnosis include the recognition that normal motor development can vary during infancy, and that evidence of motor dysfunction may not be noted until 6 to 12 months of age.
As the etiology of cerebral palsy is often related to prenatal factors, maternal perception of fetal movement can be an important clue to timing and cause. Children with genetic conditions, including Prader-Willi syndrome, mitochondrial disorders, congenital myotonic dystrophy, and other abnormalities in neural development, may have maternally perceived or externally measured decreased fetal movement (126; 79; 78; 271). Identifying the etiology may be difficult. A diagnostic approach for cerebral palsy in the genomic era has been published (155). This guide provides an approach that combines clinical assessment, MRI findings, and genomic testing to assist the provider in identifying the numerous genetic etiologies comprising cerebral palsy.
Increased fetal movement may represent fetal seizures and has been associated with congenital brain malformations, including lissencephaly (206) and subsequent neonatal encephalopathy progressing to cerebral palsy (139).
Early postnatal motor signs include poor head or trunk control, persistent or asymmetric fisting, or obligatory extensor postures. Gross and fine motor development is not only delayed but is also qualitatively abnormal. Neurobehavioral signs that should raise suspicion are excessive docility or irritability. Abnormal oromotor patterns may include tongue retraction and thrust, tonic bite, oral hypersensitivity, and grimacing.
The earliest indication of significant motor disability can be the delayed disappearance of a primitive reflex or the presence of one to an abnormal degree (44). For example, the tonic labyrinthine response occurs when the neck is extended when supine and leads to shoulder retraction, leg extension, and either elbow flexion or extension and pronation of the arms. Flexion of the neck causes flexion of the extremities. An excessive tonic labyrinthine response may manifest as "posturing" or apparent early "rolling over."
Table 2. Aids to Early Diagnosis
|
• Increased suspicion from obstetric and perinatal history |
A comprehensive examination is essential to establishing a diagnosis of cerebral palsy. An important component of the examination is the determination of muscle tone: normal, hypertonic, and hypotonic. Hypertonicity can be of spastic, rigid, or dystonic type (240). Spastic hypertonicity, which is velocity dependent, is a component of the upper motor neuron syndrome, which also includes clonus, hyperreflexia, a positive Babinski response, spastic weakness, and loss of manual dexterity. Rigidity is a type of hypertonicity with co-contractions of muscle groups. It is independent of velocity and does not cause fixed postures. Dystonic hypertonicity occurs when involuntary sustained or intermittent muscle contractions cause twisting and repetitive movements and abnormal postures. When hypotonia is present and of central nervous system origin, strength is preserved; this is in contradistinction to neuromuscular hypotonia, in which strength and reflexes are depressed. The presence of ataxia, an uncommon sign in children with cerebral palsy, should focus the etiologic diagnosis on genetic disorders, including Angelman syndrome.
In addition to the formal neurologic examination, infant assessment includes observation in prone and supine positions, pull-to-sit, supported sitting, and in vertical and ventral suspension. Skill in propping on arms and hands and the ability to rotate around the body axis are noted as well as the emergence of protective postural reactions. Particular signs that are associated with an increased risk of cerebral palsy at 4 to 6 months are failure to support weight on the forearms in a prone position, to sit supported with head erect, or to show interest in surroundings or social responsiveness. Increased neck extensor and axial tone may give a false impression of good head control. Abnormalities in vertical suspension, including scissoring and “sitting in air,” merit close attention. Adduction variability and amplitude are quantifiable gait features that correlate with expert-determined gait dystonia severity in individuals with cerebral palsy. Consideration of these features could help optimize and standardize the clinical assessment of gait dystonia severity in individuals with cerebral palsy (09). Observation of abnormal general movements in the neonatal and infant period has been applied, primarily in the Netherlands, for the prediction of cerebral palsy (220; 98; 104). This method involves trained observation for the identification of patterns of spontaneous movements that result in cerebral palsy as an outcome.
Experienced clinicians include insights learned from the National Collaborative Perinatal Project, which highlighted the variable predictive capabilities of early neurologic evaluations in their diagnostic formulations. As a component of this large, multicenter study, 37,000 children were examined at the ages of 1 and 7 years to determine the frequency of resolution of abnormal neurologic signs at the age of 1 year and to investigate whether there was evidence at the age of 7 years of other neurologic, sensory, cognitive, or behavioral problems (191). Only one half of the children diagnosed with cerebral palsy at the age of 1 year carried that diagnosis at the age of 7. Of importance, however, is that children for whom a tentative early diagnosis of cerebral palsy does resolve are more likely to manifest other neurologic diagnoses, including intellectual disability (28).
Prognosis and complications
Prognosis often depends on severity of impairment and appropriate management of functional impairment. Occasionally, an etiologic evaluation is important in prognosis and recurrence risk, especially if the disease is determined to be of metabolic-genetic origin. Families and affected individuals often seek information about long-term prognosis so that preparations can be taken for appropriate medical, financial, and life care plans. Although comprehensive long-term studies are limited, the majority of children with cerebral palsy now survive into adulthood (57). However, children who are immobile and tube-fed may have a shorter life expectancy. Caution should be used in prognostication; physicians should encourage families to establish necessary plans but to not think of survival in a specific number of years.
Ongoing medical follow-up is necessary for the patient with cerebral palsy. Early neurodevelopmental assessments at 3 to 4 months chronological age reliably predict cerebral palsy and its severity at 24 to 36 months chronological age, signifying its crucial role in facilitating early intervention. However, for cognitive impairment, longer-term assessments are necessary for accurate identification (225). Adolescents and adults with cerebral palsy are at risk for secondary conditions that cause a loss of musculoskeletal function and deterioration of quality of life (82). Increased hip flexion contracture from the physician's perspective is associated with deterioration in function from a patient and a therapist's perspective (216). The spine and joints of the lower extremities are especially vulnerable to deformities derived from muscle spasticity and contracture (35; 181). For example, some adults with extrapyramidal cerebral palsy are at risk for progressive cervical spine disease, which can lead to sudden quadriplegia if untreated (106). Others may develop progressive neurologic symptoms necessitating changes in medical management (243). A study of risk factors for hip pain in cerebral palsy found that hip displacement was associated with hip pain (167). However, hip displacement was not present in the majority of painful hips. In addition to hip displacement, decreased range of motion was associated with hip pain.
Adolescents with neurodevelopmental disability are also at increased risk of premature pubertal changes when compared to the general population (249). A systematic search and review identified 47 published studies of advanced MRI to predict neurodevelopmental outcomes in preterm infants (204). Diffusion MRI and morphometry studies were the most commonly studied modalities. Extremely premature newborns are at higher risk of developing cerebral palsy. Progression of posthemorrhagic ventricular dilation as demonstrated by cranial ultrasound and the head circumference correlated with outcome. Measurements such as these may allow for additional studies comparing optimal treatment protocols (196).
Lifestyle planning depends on multiple factors. Individual achievement is related to physical function, intelligence, ability to communicate, and personality attributes (175). Children with cerebral palsy benefit from a strong, continuing program of support services to facilitate their assimilation into the community. Social and environmental factors play an important role and accentuate the importance of early support and guidance; the availability of training, jobs, sheltered employment, and counseling contribute to the adjustment of adults with cerebral palsy. The presence of a supportive family and the availability of specialist medical care are also important factors. Long-term planning and preparation are imperative, particularly when all indications point toward the need for an ongoing support system.
Although the prognosis prediction for individuals with cerebral palsy continues to improve, the population retains higher mortality rates than the general population (255). There is an elevation in death from brain and breast cancer; respiratory, circulatory, and digestive disease; and from external causes such as drowning or motor vehicle accidents (254). Underlying causes of death among adults with cerebral palsy in the United States from a large cohort of 25,138 between 1999 to 2019 demonstrated the highest co-occurring secondary causes of death were other diseases of the nervous system (eg, epilepsy); diseases of the respiratory system (eg, pneumonia); symptoms, signs, and abnormal clinical and laboratory findings not elsewhere classified (eg, dysphagia); and diseases of the circulatory system (eg, cardiovascular disease) (213).
Biological basis
Etiology and pathogenesis
Evidence suggests that 70% to 80% of cerebral palsy cases arise from antenatal factors and that birth asphyxia contributes to approximately 10% of cases (127; 183). The majority of children (57%) are born at term (more than 37 gestational weeks) (10). In children with cerebral palsy who are born preterm, those born extremely preterm (before 26 weeks) have the highest risk (approximately 20%) of developing cerebral palsy (170). Prenatal disorders of genetic and environmental origin underlie the majority of cerebral palsy cases, with perinatal factors also playing an important role in children born preterm (99; 188). Mutations disrupting neuritogenesis genes confer risk for cerebral palsy (130).
Genetic disorders and acquired insults follow a pattern of selective vulnerability during early brain development. Cerebral malformations associated with cerebral palsy usually occur secondary to insults during the first 20 gestational weeks, and affected children are often born at term. Periventricular white matter is more susceptible to hypoxic and infectious insults during weeks 24 to 34 of gestation. At term, the basal ganglia, thalamus, and cortical gray matter are variably susceptible to hypoxia-ischemia. Perinatal stroke is a known risk factor for cerebral palsy and was detected in 12% of neonates having cardiopulmonary bypass (267). Those undergoing the Norwood procedure have a 3-fold risk of injury. In this study, stroke was associated with neurodevelopmental disability at 12 months of age (267).
Exome sequencing is a first-tier diagnostic test for individuals with neurodevelopmental disorders. For cerebral palsy, the diagnostic yield is about 27% to 35%, and it is higher among children and studies that used exclusion criteria for patient selection. This is similar to the yield for neurodevelopmental disorders for which exome sequencing is recommended as the standard of care (88). These data provide evidence to support exome sequencing in the diagnostic evaluation of individuals with cerebral palsy.
Recognized causes include developmental brain malformations such as lissencephaly, schizencephaly, Dandy-Walker syndrome, TORCH (toxoplasmosis, rubella, cytomegalovirus, herpes) infections, and in utero vascular events. Important antecedents include prematurity, low birth weight, breech presentation, maternal chorioamnionitis, thrombophilic disorders (148), complicated neonatal course, asphyxia, and infection. In preterm infants, perinatal events, including maternal chorioamnionitis, hypoxic-ischemia, and infection, are important antecedents (201). Maternal risk factors include intellectual disability, epilepsy, diabetes, and thyroid disease (127). Only 10% to 20% of cases are acquired after the prenatal period and are usually related to central nervous system infection, trauma, strokes, and severe hypoxic events such as near-drowning. A publication by Chin and colleagues showed processes with direct central nervous system involvement (eg, perinatal hypoxic-ischemic encephalopathy or infectious encephalomalacia) carry a greater than 10% absolute risk of cerebral palsy (47). Other acute perinatal processes, including placental abruption, uterine rupture, and neonatal sepsis, are also associated with increased risk of cerebral palsy but carry less than 3% absolute risk of cerebral palsy. Indirect markers of chronic placental insufficiency, such as fetal and placental growth patterns, are associated with an increased risk of cerebral palsy, and the risk of cerebral palsy in infants with growth abnormalities born extremely preterm exceeds 10%. Causal links remain incompletely understood, but genetic background, the intrauterine environment, general fetal health, and fetal neurologic health all appear to contribute (47).
Bilateral spasticity
Spastic diplegia. Spastic diplegia is most commonly a disorder of developing white matter and is nearly always associated with neuropathological and neuroimaging findings of periventricular leukomalacia (270), but may also be secondary to periventricular hemorrhagic infarction and posthemorrhagic hydrocephalus. Congenital HIV (177), familial spastic paraparesis (143; 58), structural cord lesions (69), as well as other uncommon disorders, including Sjögren-Larsson syndrome (274) and arginase deficiency (219) may have similar clinical findings but distinctive imaging findings. If upper extremity neurologic examination is normal in a child with "spastic diplegia,” brain and spine imaging should both be obtained to exclude a cord lesion as the cause (232).
Spastic quadriplegia. Spastic quadriplegia is associated with a wider range of pathological insults than spastic diplegia, including severe periventricular leukomalacia or hypoxic-ischemic encephalopathy, genetic and developmental brain malformations, hydrocephalus of various causes, TORCH infections, meningitis, and non-accidental trauma (14; 270).
A number of children have relatively symmetric destructive lesions of the cerebral cortex. One important type of destructive lesion is multicystic encephalomalacia, which refers to multiple cystic cavities in the cortex separated by glial septations. It can be the end result of intrauterine infections, severe perinatal hypoxic-ischemic encephalopathy, perinatal herpes simplex virus, bacterial meningitis, or non-accidental trauma during infancy.
A second recognized subgroup includes patients with genetic and developmental brain malformations such as holoprosencephaly, agyria-pachygyria complex (including lissencephaly), bilateral schizencephaly, and agenesis of the corpus callosum, which commonly lead to microcephaly and spastic quadriplegia (157; 101). TORCH infections, especially cytomegalovirus, can also result in pachygyria, with similar clinical findings (109).
A third subgroup includes those with fetal or neonatal hydrocephalus, reflecting a variety of pathologies affecting the development and maintenance of CSF pathways, including aqueductal stenosis and Dandy-Walker syndrome (94).
Unilateral spasticity
Spastic hemiplegia. A higher proportion of patients with hemiplegic cerebral palsy are born at term than those with diplegia or quadriplegia. Five groups of disorders are associated with spastic hemiplegia: (1) brain malformations such as unilateral schizencephaly, (2) in utero cortical-subcortical lesions, (3) abnormalities of periventricular white matter, (4) perinatal-stroke (154) as well as asymmetric grade 4 intraventricular hemorrhage, and (5) postnatal strokes (16; 50; 258; 75). Underlying genetic factors, including homeobox gene EMX2 in schizencephaly (36) as well as thrombophilic risk factors, including factor V Leiden (261; Harum and Hoon 1999), may be present. With the increased availability of imaging, cerebral infarction in term infants is more frequently diagnosed. The presence of multiple risk factors, including infertility, preeclampsia, oligohydramnios, prolonged rupture of membranes, and chorioamnionitis, significantly increases the risk of perinatal arterial stroke (154). The most common presentation is neonatal seizures. EEG and evaluation for associated prothrombotic disorders may refine prediction of prognosis (174).
Extrapyramidal (dyskinetic)
The group of patients with extrapyramidal cerebral palsy demonstrates a heterogeneous etiology. A wide range of acquired and inherited disorders of the basal ganglia are responsible in some patients (119). Two recognizable newborn encephalopathies frequently resulting in extrapyramidal cerebral palsy include (1) perinatal hypoxic-ischemic encephalopathy, with areas of hyperintense signal in the putamen, thalamus, and motor strip, often leading to athetosis and dystonia; and (2) kernicterus, with hyperintense signal in the globus pallidus and the later development of choreoathetosis (132).
Inborn errors of metabolism may present as extrapyramidal cerebral palsy. Prominent lesions in the basal ganglia, present in glutaric aciduria type I (182) and juvenile Huntington disease (156), may have an extrapyramidal phenotype. Methylmalonic aciduria can present with prominent lesions of the globus pallidi after metabolic “strokes” (110). Patients with other more obscure disorders of intermediary or neurotransmitter metabolism, or of idiopathic or genetic dystonia, may present initially as extrapyramidal cerebral palsy.
Important treatable forms of extrapyramidal cerebral palsy include pediatric neurotransmitter diseases. These rare neurometabolic disorders cause severe, often progressive neurologic symptoms and are classified on the basis of alterations in neurotransmitter metabolic pathways. They include disorders of monoamine and gamma-aminobutyric acid (GABA) metabolism (208). Although individual disorders may be diagnosed with plasma amino acid or urinary organic acid analysis, carefully collected and analyzed CSF is the best method for diagnosis (11). The prototypic treatable pediatric neurotransmitter disorder is dopa-responsive dystonia, a defect in GTP cyclohydrolase (Segawa disease), which may present with severe idiopathic extrapyramidal cerebral palsy (or spastic diplegia) early in life (145) and a normal brain MRI. Treatment with levodopa can be beneficial, with returns in motor function (195).
Hypotonia and ataxia
Hypotonic and ataxic individuals represent a diverse group of both recognizable as well as currently undiagnosed genetic and metabolic disorders. Patients are usually term infants, so this group is probably the least likely of all the cerebral palsy syndromes to be caused by an acquired condition such as asphyxia. Recognized disorders include Angelman syndrome (275), ataxia-telangiectasia (40), congenital malformations of the cerebellar vermis with mega-cisterna magna, mitochondrial disorders, carbohydrate-deficient glycoprotein disorder (171), disorders of neurotransmitter metabolism, and Joubert syndrome.
Cerebral palsy results from disorders that disrupt developing neuronal networks in cortical and subcortical pathways controlling movement. The pathogenesis and pathophysiology of cerebral palsy are strongly linked to three important concepts: (1) etiology is often linked to specific disorders of genetic and environmental origin; (2) timing and severity of insults are related to clinical syndromes; and (3) during periods of active early development, vulnerability exists for specific cell populations, and brain regions are particularly susceptible to injury on the basis of age-dependent changes in cellular metabolism, neuronal connectivity, and circulation, termed “selective vulnerability” (60; 133; 190).
Early insults or genetic abnormalities affecting fetal brain development often affect the brain globally. By the late second or early third trimester, developing oligodendroglia in periventricular white matter are vulnerable to injury (199; 60), which can be triggered by hypoxia-ischemia, infection, or maternal metabolic abnormalities involving thyroid function and glucose homeostasis (132; 64). Neuropathology reflects focal components of complete necrosis deep in the cerebral white matter and diffuse injury to oligodendroglia precursors in the surrounding area (269). Pathogenesis of periventricular leukomalacia is related to three factors: (1) immaturity of cerebral blood vessels, (2) immaturity in the regulation of cerebral blood flow, and (3) selective vulnerability of developing oligodendroglial cells to infectious, hypoxic-ischemic, or possibly endocrinological insults. Glutamate released during ischemic episodes appears to trigger excitotoxic injury in immature oligodendroglia, in part because these cells are less protected from oxygen-free radical damage than more mature cells (199). Even for affected babies born at term, periventricular leukomalacia is commonly of prenatal origin (176).
As the fetus approaches term, the vulnerability shifts from the white matter to neuron populations in the cerebral cortex and basal ganglia. Characteristic patterns on MRI include hyperintense signals in the putamen and ventrolateral thalamus, parasagittal cortical infarction, and multicystic encephalomalacia (136).
Children born prematurely, in breech presentation, or with major and minor malformations (192; 54) have an increased risk of cerebral palsy, as the difficulties probably reflect abnormal prenatal development. In particular, risk increases with increasing prematurity. Low birth weight makes preterm infants especially vulnerable to complications that can increase the risk of cerebral palsy. For instance, babies needing mechanical ventilation can develop bronchopulmonary dysplasia that can then lead to prolonged periods of hypoxemia.
An association exists between prenatal brain damage and multiple gestations; the prevalence of cerebral palsy is reported to be six times higher in twins than in singletons (186). Causes include low birth weight, congenital anomalies, cord entanglement, vascular shunts between twins, and abnormal vascular connections. If one twin dies in utero, a release of thromboplastins and emboli may occur. If the death occurs during early pregnancy, the surviving twin may develop cerebral dysgenesis (18). Twins are also more likely to develop antenatal periventricular leukomalacia, and the risk of cerebral palsy is greater in those who survive the fetal death of a co-twin. The risk also increases the higher the multiple gestations (214).
Other risk factors include male gender and older siblings with cerebral palsy. Preexisting maternal conditions that increase risk include stroke, autoimmune disorders, thrombophilic disorders such as factor V Leiden mutation, intrauterine growth restriction, and perinatal infection. Infection and inflammation are linked to a hypothesis implicating cytokines, including tumor necrosis factor, which are produced on microbial invasion of the amniotic fluid and can produce adverse effects on the developing brain (127). Research studying the placenta in preterm births suggests connective tissue inflammation of the umbilical cord is associated with cerebral palsy (159).
Advances in neuroimaging using diffusion imaging and diffusion tensor imaging promise to further the understanding of the pathogenesis and pathophysiology of cerebral palsy (248; 123; 179; 121; 251). For example, although cerebral palsy is believed to result from injury or maldevelopment in efferent motor pathways, it may also result from sensory tract dysfunction (24; 116). Hoon and coworkers mapped injured white matter pathways in two children with cerebral palsy associated with preterm birth (117). Three-dimensional reconstructions of white matter pathways in these two children show that the primary injury was in sensory pathways in the brain. Studies involving altered sensorimotor cortical activity demonstrate spinal cord microstructural changes may represent activity-dependent plastic changes (263). Findings support the work of those who believe a component of rehabilitation involves activities such as hippotherapy (therapeutic horseback riding), which may be effective through activation of sensory pathways.
Epidemiology
The overall prevalence of cerebral palsy is about 3.6 per 1000 live births (184; 99; 284). Despite dramatic improvements in obstetrical and neonatal intensive care, this figure has remained relatively constant over the last two decades. However, a nationwide study in Japan suggests the prevalence of periventricular leukomalacia has decreased significantly (256). There may be a trend in Europe toward decreasing prevalence of cerebral palsy. Data were collated from 20 population-based registers contributing to the Surveillance of Cerebral Palsy in Europe database; the overall prevalence of cerebral palsy decreased from 1.90 to 1.77 per 1000 live births. This was reported to be due to the decline in prevalence of cerebral palsy in children of very low birth weight (VLBW), and it confirmed what was previously reported (244). Rates of early neurodevelopmental impairment in extremely preterm infants have changed little despite significant improvements in overall survival (229). Efforts to provide family-centered medical, developmental, and social support systems can benefit patients and families for a lifetime after extreme preterm birth.
Prematurity is strongly associated with cerebral palsy (257), although 58% of cases are born at term (10). Despite the focus on prevention in industrialized countries, including the United States (265), preterm birth has increased in the last decade. Subgroup studies of the 1980s and 1990s show that white women had a greater increase in medically indicated, rather than spontaneous, preterm birth, whereas black women saw increases in both. Both had decreases in preterm deliveries due to ruptured membranes (08).
The improved survival of very low birth weight infants has increased the absolute number of children with cerebral palsy (278). A related factor is the increase in multiple births, where infants are more likely to be of low birth weight and, therefore, at increased risk (91). Although most premature infants do develop normally, concerns have arisen that one undesirable effect of improved neonatal care is the increased survival of children with severe neurodevelopmental handicaps, such as cerebral palsy (96; 53). Furthermore, in some preterm children with normal intelligence at school age, a wide variety of more subtle motor and behavioral problems are seen (273).
From 2001 to 2013, NIH funding, averaging $30 million per year, supported clinical ($215 million), basic ($187 million), and translational ($26.3 million) cerebral palsy-related research (283). Clinical intervention studies comprised 19% of funding and focused on treatments ($60.3 million), early parent intervention ($2.7 million), and cerebral palsy prevention ($2.5 million). Among grants that specified gestational age, more funds were devoted to preterm ($166 million) than term infants ($15 million). Cerebral palsy in adulthood was the main focus of 4% of all funding. Annual NIH funding for cerebral palsy increased steadily over the study period from $3.6 to $66.7 million. However, funding for clinical intervention studies peaked in 2008, and it has since decreased (283).
The Danish Cerebral Palsy Follow-up Program is currently under development as a national clinical quality database in Denmark. The database holds potential for research in prevalence, clinical characteristics of the population, and the effects of prevention and treatment (224).
Prevention
At present, the majority of cases of cerebral palsy are difficult to predict or prevent (175; 147). Individual events such as meconium-stained fluid, early low Apgar scores, delayed onset of respirations, and acidosis in the absence of neurologic abnormalities do not reliably predict cerebral palsy. Despite dramatic improvements in neonatal and obstetric medicine, there has been little change in the incidence of cerebral palsy over the last two decades. This suggests that neither sophisticated fetal monitoring, obstetrical interventions, nor increased rate of Caesarean section have had much impact in reducing the incidence of cerebral palsy (41; 241; 203; 51).
A number of identifiable causes of cerebral palsy are currently preventable or treatable. Vaccinations against infectious agents such as rubella and Haemophilus have decreased the incidence of these infectious disorders associated with cerebral palsy (231). Maternal treatment for Group B streptococcal colonization has been effective in decreasing neonatal sepsis and meningitis (25). Rhogam, phototherapy, and exchange transfusion can prevent kernicterus and the development of extrapyramidal cerebral palsy (65). Postnatal risk can be minimized through the prevention of accidental injury. Given the significant contribution of maternal and prenatal infection to the risk of cerebral palsy, this area holds great potential for risk prevention in the future (217; 242). This is supported in the reduction of vertical transmission of HIV by maternal administration of antiretrovirals (43).
Growth restriction may be a significant risk factor for cerebral palsy (29). The risk of cerebral palsy was found to be increased in antenatally growth-restricted singletons born at or near term to normotensive mothers. In growth-restricted singletons, a major birth defect was the dominant predictor, associated with a 30-fold increase in the odds of cerebral palsy. Identification of birth defects in the growth-restricted fetus or neonate may provide significant prognostic information (29).
Maternal thyroid hormone is important for fetal brain development (266). In regions of the world where there is severe endemic iodine deficiency with associated microcephaly, spasticity, and cognitive impairment, maternal supplementation during early pregnancy improved neurologic and cognitive function (42). Maternal thyroid hormone crosses the placenta and may affect fetal brain development by several mechanisms (02; 238).
A report using the Cochrane Pregnancy and Childbirth Group's Trials Register provides evidence for not giving antibiotics routinely to women in preterm labor with intact membranes in the absence of overt signs of infection (77). A large population-based study in Sweden showed of children born extremely preterm and receiving active perinatal care, 73% had mild or no disability, and neurodevelopmental outcome improved with each week of gestational age (245). These results are relevant for clinicians counseling families facing extremely preterm birth.
An exciting area of study is neuroprotection in term infants with hypoxic-ischemic encephalopathy (259; 71). Selective head cooling has been considered a neuroprotective therapy in term neonates with perinatal asphyxia due to its ability to slow the cascade of hypoxic-ischemic injury. Studies have investigated moderate hypothermia as a treatment for perinatal asphyxial encephalopathy. The TOBY Study group demonstrated moderate hypothermia does not reduce rates of death but does improve neurologic outcomes, including cerebral palsy in survivors (12). A meta-analysis of 10 trials encompassing 1320 infants showed that in infants with hypoxic ischemic encephalopathy, moderate hypothermia is associated with a reduction in death and neurologic impairment at 18 months (68). A National Institutes of Health outcomes study of 190 participants showed the rate of the combined end point of death or an IQ score of less than 70 at 6 to 7 years of age was lower among children undergoing whole-body hypothermia than among those undergoing usual care, but the differences were not significant. However, hypothermia resulted in lower death rates and did not increase rates of severe disability among survivors (246). Neonatal therapeutic hypothermia is expanding in many neonatal intensive care units. Overall, studies show that moderate hypothermia within 6 hours of asphyxia improves survival without cerebral palsy or other disability by about 40% and reduces death or neurologic disability by nearly 30% (134). Research is underway to discover adjuvant treatments such as xenon, topiramate, erythropoietin, melatonin, anti-inflammatory agents, growth factors, and molecular and cell-based therapy to enhance the effects of hypothermia (134; 228).
A randomized trial of erythropoietin for neuroprotection in preterm infants demonstrated that high-dose erythropoietin treatment administered to extremely preterm infants from 24 hours after birth through 32 weeks of postmenstrual age did not result in a lower risk of severe neurodevelopmental impairment or death at 2 years of age (137).
In high-risk extremely low birth weight infants, stress dose hydrocortisone therapy after 10 days of age had no statistically significant effect on the incidence of death or neurodevelopmental impairment at 18 to 22 months (205). Magnesium given prior to preterm delivery is associated with decreased risk of developing echodensities and echolucencies at less than 32 weeks gestation, which may partially explain the effect of magnesium decreasing the risk of cerebral palsy at 2 years of age (112). Systemic administration of a single dose of dendrimer-N-acetyl cysteine conjugate (D-NAC) at either subacute or delayed time points after injury results in sustained attenuation of the “detrimental” proinflammatory response up to 9 days after injury, while not impacting the “favorable” anti-inflammatory response. The D-NAC therapy also led to improvement in myelination, suggesting reduced white matter injury (185).
Morioka and colleagues demonstrated that periventricular leukomalacia-like brain injury in neonatal rats and human umbilical cord-derived mesenchymal stem cell infusion ameliorated dysmyelination in lipopolysaccharide-induced neonatal rat brain injury (180). Preconditioning of umbilical cord-derived mesenchymal stem cells improved neuroprotective effects.
Reviews have been published showing the emergent prophylactic, reparative, and restorative brain interventions for infants born preterm with cerebral palsy (76).
Differential diagnosis
As the definition at the beginning of this article indicates, a wide range of genetic and acquired disorders are included as cerebral palsy. The primary distinction is from severe neurodegenerative disorders that usually lead to death, including progressive white matter disorders such as adrenoleukodystrophy and metachromatic leukodystrophy, and a wide range of storage disorders, including the gangliosidoses and neuronal ceroid lipofuscinosis. Repeated examination is necessary to detect developmental changes that might be consistent with a progressive disorder. Rapidly evolving signs, in particular changes in muscle tone, suggest a neurodegenerative disorder. Patients with some progressive disorders, such as pantothenate kinase-associated neurodegeneration, may progress at such a slow rate initially that they appear to have idiopathic extrapyramidal cerebral palsy. Deterioration that appears to suggest a progressive disorder can also derive from an increase in contractures, anticonvulsant toxicity, and undiagnosed or intractable epilepsy. The differential diagnosis also includes developmental or traumatic lesions of the spinal cord, severe neuromuscular disorder, and neoplasm.
In the intellectual disability syndromes, primitive reflexes are usually appropriate, but the motor development and the appearance of postural reflexes may be delayed. Practically all children with severe intellectual handicap have some motor disorder that expresses itself in a pattern inappropriate to their chronological age. Cerebral palsy is present when, in addition to the intellectual impairment, a motor disorder as described above is seen.
Diagnostic workup
As in other areas of medicine, the diagnostic workup of children with motor delay may require the input of a number of medical specialists as well as that of physical and occupational therapists. Those responsible for coordinating the evaluation should be experienced with the medical and rehabilitative needs of children with cerebral palsy. They should also be aware of the feelings of guilt and apprehension present in families. A marked delay in age at initial referral of children with cerebral palsy to medical and rehabilitation specialists was found by Boychuck and colleagues (32). A minority of referrals came from primary-care providers, which is of concern given their vital role in early detection of developmental disabilities. More than half of children with cerebral palsy do not have a complicated birth history, and referrals for diagnosis and management for these children were postponed, often beyond 3 years (32).
A careful history should include details of the prenatal, perinatal, and postnatal course. Maternal perception of decreased fetal movement is an important sign of prenatal onset. Early identification of cerebral palsy using neonatal MRI and the General Movements Assessment has been studied in a cohort of high-risk term neonates. Normal neonatal MRI and General Movements Assessment at the age of 3 months are reassuring that a high-risk term-born child is at low risk for moderate to severe cerebral palsy (85). Family history is important to identify potential genetic disorders. The systems review should include questions about vision, hearing, snoring, feeding, bowel, and bladder function, as well as any cardiac and pulmonary problems. The neurologic examination should be comprehensive, including careful observation for adventitious movements, including chorea, athetosis, hemiballismus, and dystonia. The functional assessment for children with cerebral palsy is best done in conjunction with skilled physical and occupational therapists. Children can be classified both by the extent of necessary mobility aids (from point canes to wheelchairs) as well as by their ability to ambulate independently in various settings.
There are limited data on cognition in childhood dystonia. Coenen and colleagues showed that primary dystonia showed intact cognition and IQ, but mild working memory and processing speed deficits (52). Secondary dystonia showed more pronounced deficits and lower IQ, with frequent intellectual disability. In combination with a thorough history and examination, neuroimaging techniques, including brain MRI, may provide benefit in recognition of etiologic disorders, management, prognosis, and assessment of recurrence risk (155). This is important because there are a number of treatable inborn errors of metabolism that mimic cerebral palsy (153). Neuroimaging techniques may uncover an underlying pathogenesis for many of the causes of cerebral palsy, including cerebral lesions, asphyxia, and genetic and metabolic disorders (194; 131; 121; 117). Imaging techniques should be selected based on the advantages and disadvantages of each technique as well as the sedation requirements for patients. MRI in particular has proved the greatest use in children with cerebral palsy as it can differentiate white and grey matter more clearly than CT scans (114). Seventy percent to 90% of affected individuals will have abnormalities on MRI (15; 118). Cranial ultrasound remains the most common technique for preterm neonates. Thirty-one articles met the inclusion criteria, five of which reported diagnostic accuracy and five reported data sufficient for calculation of diagnostic accuracy. Early structural MRI global scores detected a later diagnosis of cerebral palsy with a pooled sensitivity of 100% (95% confidence interval [CI] 86-100) and a specificity of 93% (95% CI 59-100). Global structural MRI scores determined adverse motor outcomes with a pooled sensitivity of 89% (95% CI 44-100) and a specificity of 98% (95% CI 90-100). White matter scores determined adverse motor outcomes with a pooled sensitivity of 33% (95% CI 20-48) and a specificity of 83% (95% CI 78-88).
Diffusion tensor imaging, which demonstrates preferential water diffusion along axonal tracts, is an area of great promise for identifying abnormalities of white-matter pathways, such as periventricular leukomalacia (114). Developmental abnormalities are being measured quantitatively using anatomic MRI and diffusion tensor imaging during multiple stages of brain development (198).
MRI findings can determine the need for additional testing (233). For example, in a child with extrapyramidal cerebral palsy and imaging abnormalities in the globus pallidus, a comprehensive evaluation for genetic-metabolic disorders should be conducted. In those with developmental brain malformations, including neuronal migration disorders such as lissencephaly and schizencephaly, specific molecular testing may be important to identify an etiology and determine recurrence risk (86). If evidence is found in a clinical examination to suggest a genetic etiology, a karyotype as well as specific molecular probes should be obtained. In addition to brain MRI, the etiologic evaluation of extrapyramidal patients should include urine organic acids, plasma amino acids, lactate, and chromosomes. Evaluation of CSF biopterin, neurotransmitter, and amino acid metabolism is often indicated, especially in patients with idiopathic extrapyramidal cerebral palsy with normal MR scans. Careful follow-up is important because categories of disease continue to be established, such as the cholesterol synthesis abnormalities in Smith-Lemli-Opitz (200) and carbohydrate-deficient glycoprotein disorders (93). Magnetic resonance spectroscopy assessment of the brain after moderate hypothermia in neonatal hypoxic-ischemic encephalopathy is being studied by the MARBLE consortium (150).
Neurophysiologic studies show that motor performance errors of children with cerebral palsy are linked with neural synchronization within the somatosensory cortices (149).
In general, all children with cerebral palsy should receive an ophthalmological evaluation, both to detect ocular abnormalities suggestive of specific disorders and to treat the refractive errors frequently present.
Genetic studies have been a topic of interest to predict cerebral palsy and disease severity. There is an expanding role for genetics in cerebral palsy (73). According to a large study of patients, the molecular diagnostic yield of exome sequencing in identifying a pathologic variant in patients with cerebral palsy is 32.7% in pediatric patients and 10.5% in adult patients (178). In a meta-analysis of exome sequencing yield in cerebral palsy, the overall diagnostic yield was 23%. The diagnostic yield across cryptogenic cerebral palsy was 35% compared with noncryptogenic cerebral palsy at 7% (252). A study shows vasoactive intestinal polypeptide and GRIN3A SNPs may be associated with cerebral palsy at 2 years of age in children born preterm (56). Another study showed two IL18 loci SNPs (rs549908:A> C and rs1290349:C> A) had a protective effect against spastic cerebral palsy, and interestingly, both were associated with a decreased epidemiological expression of IL18 protein (113). These preliminary new data combining protein to genetic information also suggest IL18's involvement in the pathogenesis of spastic cerebral palsy. Pathogenic copy number variants may also impact the genomic burden in cerebral palsy (55).
Early markers of clinical phenotype and functional outcome have been studied (72). Aberrant general movements at 10 to 15 weeks post-term are associated with adverse neurodevelopmental outcomes and specific white matter microstructure abnormalities for cognitive, language, and motor delays (215).
Management
A multidisciplinary team approach is required to care for people with neurodevelopmental disorders such as cerebral palsy (262). Effective management of cerebral palsy requires a team with medical and rehabilitative specialists to provide careful, ongoing neurodiagnostic evaluation and rehabilitation to maximize functional capabilities. Coordination of the medical team with additional community support services is necessary to ensure that affected individuals receive full opportunities to learn in school and participate in society.
Management should aim to achieve maximal potential in all areas of development and to encourage independence. An understanding of where patient function is categorized on a spectrum of severity may be helpful when developing treatment plans. Early identification and intervention for neurodevelopmental disorders have age-dependent challenges and advantages (59; 97). Realistic, functional goals must be set and periodically re-evaluated by the rehabilitative team. Treatment plans should include the principal caregivers and teachers. A number of rehabilitative motor interventions exist for individuals with cerebral palsy. Rehabilitative goals will vary by patient depending on the clinical situation, including ease of care, prevention of orthopedic deformity, or facilitating function.
A range of oral pharmacological agents are also used to treat spasticity; these include diazepam, baclofen, dantrolene, and tizanidine (218; 37). Benzodiazepines, such as diazepam, reliably produce tone reduction safely but may produce drooling and sedation. Although no controlled studies exist comparing diazepam and baclofen, the lack of cognitive side effects with baclofen have led to preferential use over diazepam. Patients should be cautioned that abrupt discontinuation of baclofen use can precipitate hallucinations and seizures and that it may precipitate seizures in young children (105).
In 2009, the American Academy of Neurology published practice parameters for the pharmacologic treatment of spasticity in children and adolescents with cerebral palsy. Recommendations support the use of botulinum toxin A for treating localized or segmental spasticity that warrants treatment (22). The simultaneous use of BoNT-A and strength training is successful in spasticity reduction, improving strength and achieving functional goals, over and above treatment with BoNT-A alone (276). Neurophysiologic tests to evaluate reduced spasticity after botulinum toxin-A injection are being investigated; tendon reflex amplitude showed the highest correlation with severity of spasticity (128). For generalized spasticity, diazepam and tizanidine should be considered for short-term treatment. There are insufficient data to support or refute the use of phenol, alcohol, botulinum toxin B, dantrolene, oral baclofen, or continuous intrathecal baclofen (222).
For patients with extrapyramidal cerebral palsy, pharmacologic agents modulating dopamine action in the striatum have proved effective. For those with chorea, drugs to deplete dopamine have been used, including reserpine and tetrabenazine (129). Benzodiazepines, including clonazepam, which potentiate GABAergic action, may also be of benefit (210). For patients with dystonia, athetosis, or bradykinesia, drugs to increase dopamine flux have been used, including trihexyphenidyl, levodopa, and carbidopa (115). Gabapentin may significantly ameliorate dystonia severity and improve activities of daily living and quality of life in children with severe dystonia (162).
Surgical procedures are common for the progressive orthopedic deformities that arise in spastic patients. Surgeon-caregiver agreement is greater where literature support for a particular surgical indication is strong (ie, spinal fusion's known improvement of sitting posture in children with neuromuscular scoliosis). Stronger literature support may bolster surgeons' confidence in recommending a particular procedure, fostering greater communication, understanding, and agreement on surgical necessity between caregivers and surgeons (01). These operations have advanced from solo, sequential procedures to simultaneous, collective procedures, including both soft tissue and bone work (74). Soft tissue procedures allow for muscle lengthening. Bone procedures are typically localized to the leg, hip, and spine. Videotaped gait analysis can be used to focus surgical intervention and to measure postoperative success (30). It is unclear at this time whether pharmacological interventions will lessen the need for orthopedic surgery in the future. Scoliosis is a common comorbidity in children with cerebral palsy. A multinational study identified truncal tone disorders, intractable epilepsy, and female gender as predictors of scoliosis in subjects with cerebral palsy (26). These data support increased frequency of spine and spine x-ray examinations in this population to identify candidates for treatment.
For children with severe cerebral palsy, refractory to standard interventions, neurosurgical procedures, including intrathecal baclofen, selective dorsal rhizotomy, and deep brain stimulation, should be considered (05). A prospective study confirms the benefit of single-event multi-level surgery, showing clinically and statistically significant improvements in gait and function in children with bilateral spastic cerebral palsy, which were maintained at 5 years after surgery (260).
Intrathecal baclofen is an efficacious therapy for the treatment of hypertonicity. Intrathecal baclofen has been employed for patients with more severe degrees of spasticity of cerebral as well as spinal origin (209; 04). Drug dosages are delivered by a programmable pump placed in the abdomen and connected to a catheter that ends in the intrathecal space. Studies have indicated that intrathecal baclofen effectively reduces spasticity (84) and improves function (152; 250). The drug has also been reported to be of benefit in dystonic cerebral palsy (06). However, the determination of suitable candidates is ongoing (39). Complications of intrathecal therapy can include catheter kinking and infection, which can require replacement of either the catheter or pump. Dose-related side effects include confusion and lethargy. The presence of an intrathecal baclofen pump for spasticity appears to be associated with the increase in scoliosis progression, and these patients will likely have a more challenging spine fusion (161). Fortunately, the final outcome is not affected by intrathecal baclofen pump.
Interest has arisen in stereotactic neurosurgical procedures similar to those performed for Parkinson disease patients (63). Depending on the clinical setting, both ablative and neural stimulation procedures may be used. In carefully selected patients, the severity of dystonia and hemiballismus may be decreased. However, hardware complications are significant (197). Deep brain stimulation has been considered in patients with cerebral palsy and is being used on selective subgroups (140). The outcome is encouraging in most dystonic cerebral palsy patients, with a stable outlook and a good safety profile (230). Further studies are required to elucidate the risk versus benefit in such neuroinvasive therapies.
Dorsal rhizotomy (transaction of selected sensory nerves entering the lower spinal cord) decreases spasticity in associated muscles but can have unwanted side effects on bowel and bladder function. The treatment should be performed in conjunction with physiotherapy and is only recommended for persons with severe lower extremity spasticity for whom other treatments have been unsuccessful (87). The ideal candidates are believed to be young children who were born prematurely and have good antigravity strength. Both medical and orthopedic surgical techniques can target symptoms at the musculoskeletal level, with goals of relaxing muscles and realigning the skeleton. One study confirms that the benefits of selective dorsal rhizotomy are long-lasting and positively alter the natural history of spastic cerebral palsy (67). Botulinum toxin can be injected into the neuromuscular junction of either dystonic or spastic muscles and has been effectively used on patients with localized spasticity to improve their gross and fine motor abilities (280; 144). Botox will relax muscles for a period of 4 to 6 months. Results improve if treatment is paired with splinting and physiotherapy. Children with greater motor involvement, as indexed by GMFCS level, may be at risk for increased pain (intensity, frequency, and duration) that interferes with activities of daily living (17).
Nanomedicine offers the opportunity to deliver agents that would promote repair and regeneration in the brain, resulting not only in attenuation of injury, but also enabling normal growth. Advances in nanotechnology for treatment of brain injury that results in cerebral palsy are being investigated to facilitate clinical translation in neonates and children (13). Other novel therapies such as stem cells have been studied for many years (207).
Physical, occupational, and speech therapies are employed as initial therapies or used in conjunction with medical and surgical treatments, focusing on improving the strength and motion of affected muscles. Language impairment is common in children with cerebral palsy, affecting three of five children (173). These findings suggest most children would benefit from a clinical language assessment. Studies that evaluate dosing parameters of physical therapy for patients with cerebral palsy are a priority (83). Occupational and physical therapy play a fundamental role in children (19). Techniques serve to lessen the effects of inhibitory reflexes, facilitate the acquisition of gross and fine motor skills, and to encourage language and the promotion of confidence and self-esteem. Sophisticated technological aids may play an important role; these include motorized wheelchairs, voice-activated computers, and various switching devices that can be used to activate communication systems. Mobility aids should work in conjunction with physical therapy to progress toward maximum patient independence. Constraint-induced movement therapy (CIMT) has received attention as a therapeutic intervention for patients with stroke or hemiplegic cerebral palsy. Several randomized clinical trials have evaluated the impact of dosing frequency and intensity in children with cerebral palsy (33; 89; 237; 223). Constraint-induced movement therapy and repetitive transcranial magnetic stimulation (rTMS) are emerging as effective interventions in improving motor function in hemiplegic cerebral palsy (22; 124; 95). Pediatric CIMT at both moderate and high dosages produce positive effects across multiple reliable, valid outcome measures (62). For school-aged children with unilateral cerebral palsy, a half dose (30 h) of either modified CIMT or bimanual therapy may not be sufficient to impact upper limb outcomes, but patients will have clinically meaningful gains in occupational performance (236). The Gross Motor Function Measure-88 can be reliably scored using video recordings (80). Robotic-assisted gait training (RAGT), using a device such as the Lokomat®Pro, may permit longer training duration and faster and more variable gait speeds as well as support walking pattern guidance more than overground/treadmill training to further capitalize on motor learning principles (111). Hilderley and colleagues reported the first randomized controlled trial comparing RAGT to an active gait-related physical therapy intervention in pediatric cerebral palsy that addresses gait-related gross motor, participation, and individualized outcomes (111). As such, the study is expected to provide comprehensive information as to the potential role of RAGT in clinical practice.
Treadmill training may improve the walking speed and gross motor function of adolescents with spastic cerebral palsy without adverse effects on spasticity (49). A review of the utility of functional electrical stimulation in cerebral palsy shows promise for treatment benefit (282). Game systems such as the Nintendo Wii have shown potential for use as a rehabilitation tool in managing children with cerebral palsy (90; 38). Clinical trials are being considered for these entertainment-related therapies. Cognitive studies suggest that the consequence of error-making on future performance is intact youth with mild spastic cerebral palsy, but the study group was small, and replication is required (102). Novel mobility training methods are also showing promise for altering the motor disability trajectory in children with cerebral palsy (221). Electric stimulation has been studied as a potential treatment for reducing aspiration in cerebral palsy (165; 168). Interest in the outcomes of children with unilateral cerebral palsy has prompted a study by Klingels and colleagues (142). Over five years, children with unilateral cerebral palsy develop more limitations in premature rupture of membranes, and although capacity measures improve, the spontaneous use of the impaired limb in bimanual tasks becomes less effective after the age of 9 years.
Some patients and their families choose to supplement care with complementary therapies, and physicians should be aware of those that exist. Alternative medicine strategies for cerebral palsy include hyperbaric oxygen, the Adeli suit program, aquatherapy, hippotherapy, chiropractic, massage, and acupuncture sessions, conductive education, patterning, and prayer and music therapy. Uncontrolled and controlled trials of hippotherapy have shown beneficial effects on body structures and functioning. Studies of acupuncture are promising, but insufficient data exist to make specific recommendations. Most studies of patterning have been negative. Insufficient data exist to make specific recommendations on hyperbaric oxygen. There is growing interest in acupuncture intervention for cerebral palsy. One study from China shows that acupuncture with sitting training is better than sitting training intervention alone in improving cerebral palsy children with parafunctional sitting position, especially for the spastic and hypotonic cerebral palsy patients (285). In summary, limited literature exists on the effectiveness and safety of complementary and alternative medicine in pediatric populations, so physicians should use their best judgment in integrating medical treatments with alternative therapies (34; 163). More research based on high-quality studies focusing on functioning in all dimensions of the International Classification of Functioning, Disability, and Health perspective is necessary to clarify the impact of suit therapy (172). Auditory stimulation has been studied to improve motor function and caregiver burden (23).
The prevalence of chronic conditions among adults with cerebral palsy is higher than adults without cerebral palsy. Adults with cerebral palsy are more likely to have type 2 diabetes, anxiety, bipolar disorder, depression schizophrenia, hypertension, ischemic heart disease, stroke, cerebrovascular disease, asthma, liver disease, osteoarthritis, osteoporosis, underweight, and chronic kidney disease than adults without cerebral palsy (234). Additional complications that may require management include feeding difficulties and psychosocial development. Feeding difficulties pose an additional complication for many children with cerebral palsy, particularly those with significant intellectual impairment. Coping with these difficulties can become a time-intensive part of patient management. A gastrostomy, usually in addition to a fundoplication, is often recommended. As a reliable route to the stomach, a g-tube can allow for improved nutrition, weight gain, reduced aspiration, and a safer route for medication. Focusing attention on improving nutrition early in the lives of children with cerebral palsy affords families and care providers with a unique opportunity for intervention that may result in better outcomes for the children (226). One study suggests that oculomotor function spontaneously improves in children with cerebral palsy (70).
Chronic pain in children with cerebral palsy is not commonly identified and may lead to detriments in physical, social, and mental well-being. A consensus among inter-professional working group members from Canada published seven important chronic pain interference tools in the American Academy of Pediatrics. Not all tools have been validated with children with cerebral palsy, nor is there one tool to meet the needs of all children experiencing chronic pain (141). Studies on chronic pain in children with cerebral palsy identify a need for nonpharmacologic interventions in addition to more studies on pharmacologic interventions (158).
Early social and psychological services are vital for both the parents and the child. Psychosocial and environmental factors in school certainly impact the well-being of the family and individual with cerebral palsy (166). Physicians should discuss the diagnosis with parents honestly and sensitively, recognizing that parents must deal with large amounts of information and difficult or uncertain prognoses; they should be prepared to answer the child’s questions appropriately. With the increased responsibility of a handicapped child, parents themselves can become socially limited, putting stress on marital relationships and the nurturing of other children. Studies have shown mothers, in particular, feel the difficult implications of caregiver burden, family and social support, changing women's roles, and socioeconomic challenges that arise with caring for a child with cerebral palsy (103). Parents can express dissatisfaction and even resentment toward the physician, reacting with sorrow, as well as denial, guilt, frustration, anger, resentment, and embarrassment. It is important to try to alleviate any guilt that may be felt with regard to causation. Counseling is a continuous process, and ready availability of experienced professionals is important.
As the affected child ages, prevocational assessment and training based on ongoing discussions become more important (46). Psychological development, communication, and education become the main priorities (175). Lifestyle management should provide a rational basis for communication and for daily living activities so that the affected individual can gain the maximal benefit from formal education. It is important for families to promote confidence and self-esteem in their children with therapeutic activities such as aquatherapy and horseback riding. Educational opportunities are available until the age of 21 years under the provisions of the Individuals with Disabilities Education Act, but services are less organized in adulthood. Despite the American with Disabilities Act, employment barriers continue to exist. Physicians and other health care providers who include adolescents with cerebral palsy in their practices should begin discussion and planning for transition to adult health care early in adolescence (27).
Chronic conditions occur more frequently in adults with cerebral palsy than without cerebral palsy and include hypertension, diabetes, stroke, joint pain, and respiratory diseases and heart diseases (212). The prevalence of sleep problems in children with cerebral palsy is high (120).
Medical doctor training in management of cerebral palsy is important; however, a significant proportion of child neurology and neurodevelopmental disabilities training programs felt that residents were not very well prepared to manage cerebral palsy. The development of cerebral palsy curricula and exposure to cerebral palsy clinics may improve training, translating to better care of individuals with cerebral palsy (277).
Outcomes
Participation of adolescents with cerebral palsy is predicted by early modifiable factors related to the child and family (61). Interventions for reduction of pain, psychological difficulties, and parenting stress in childhood are justified not only for their intrinsic value, but also for probable benefits to childhood and adolescent participation. Postmortem diagnostic overshadowing, which is defined as inaccurately reporting a disability as the underlying cause of death, occurs for over half of adults with cerebral palsy. Inaccurate reporting is associated with heightened contexts of clinical uncertainty, the false equivalence of disability and health, and potential racial-ethnic bias (151).
Special considerations
Pregnancy
Little published data are known regarding pregnancy in women with cerebral palsy. (279; 264). Helpful resources addressing the health and reproductive possibilities for women with cerebral palsy include: (108; 146). It remains unknown whether assistive reproductive therapy increases the risk of cerebral palsy (122).
Anesthesia
Special consideration should be used for anesthetizing patients with cerebral palsy in both surgical and neuroimaging situations. Anesthesiologists should be aware of particular perioperative problems, including seizure control, respiratory function, and gastroesophageal reflux. Postoperative care should carefully address pain management and the prevention of muscle spasms (193). Anesthesia for dental care may also be required (07).
In neuroimaging studies, sufficient sedation is important for avoiding excess artifact. At Johns Hopkins Hospital, chloral hydrate is usually employed for infants and young children, intravenous sodium pentobarbital for older children, and general anesthesia for those who cannot remain still independently or for whom other types of sedation fail. Children with brain malformations and genetic and genetic-metabolic disorders like cerebral palsy may have atypical reactions to sedation and require longer periods of observation following a study (114).
References
- 01
- Adams AJ, Refakis CA, Flynn JM, et al. Surgeon and caregiver agreement on the goals and indications for scoliosis surgery in children with cerebral palsy. Spine Deform 2019;7(2):304-11. PMID 30660226
- 02
- Ahlgren SC, Wallace H, Bishop J, Neophytou C, Raff MC. Effects of thyroid hormone on embryonic oligodendrocyte precursor cell development in vivo and in vitro. Mol Cell Neurosci 1997;9:420-32. PMID 9361279
- 03
- Aksu F. Nature and prognosis of seizures in patients with cerebral palsy. Dev Med Child Neurol 1990;32:661-8. PMID 2210081
- 04
- Albright AL. Baclofen in the treatment of cerebral palsy. J Child Neurol 1996;11:77-83. PMID 8881981
- 05
- Albright AL. Neurosurgical treatment of spasticity and other pediatric movement disorders. J Child Neurol 2003;18 Suppl 1:S67-78. PMID 13677572
- 06
- Albright AL, Barry MJ, Shafton DH, Ferson SS. Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol 2002;43:652-57. PMID 11665821
- 07
- American Dental Association. Oral Health Care Guidelines: Patients With Physical and Mental Disabilities. Chicago: American Dental Association Council on Community Health Hospital–Institutional and Medical Affairs, 1992.
- 08
- Ananth CV, Joseph KS, Oyelese Y, Demissie K, Vintzileos AM. Trends in preterm birth and perinatal mortality among singletons: United States, 1989 through 2000. Obstet Gynecol 2005;105:1084-91. PMID 15863548
- 09
- Aravamuthan BR, Pearson TS, Ueda K, et al. Determinants of gait dystonia severity in cerebral palsy. Dev Med Child Neurol 2023;65(7):968-77. PMID 36701240
- 10
- Ashwal S, Russman BS, Blasco PA, et al. Practice parameter: diagnostic assessment of the child with cerebral palsy. Neurology 2004:62:851-63. PMID 15037681
- 11
- Assmann B, Surtees R, Hoffmann GM. Approach to the diagnosis of neurotransmitter diseases exemplified by the differential diagnosis of childhood-onset dystonia. Ann Neurol 2003;54:S18-24. PMID 12891650
- 12
- Azzopardi DV, Strohm B, Edwards AD, et al. Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med 2009;361(14):1349-58. PMID 19797281
- 13
- Balakrishnan B, Nance E, Johnston MV, Kannan R, Kannan S. Nanomedicine in cerebral palsy. Int J Nanomedicine 2013;8:4183-95. PMID 24204146
- 14
- Barkovich AJ. Pediatric neuroimaging III. Philadelphia: Lippincott, Williams & Wilkins, 2000:157-209.
- 15
- Barkovich AJ, Kjos BO. Schizencephaly: correlation of clinical findings with MR characteristics. AJNR Am J Neuroradiol 1992;13:85-94. PMID 1595498
- 16
- Barmada MA, Moossy J, Shuman RM. Cerebral infarcts with arterial occlusion in neonates. Ann Neurol 1979;6:495-502. PMID 533248
- 17
- Barney CC, Krach LE, Rivard PF, Belew JL, Symons FJ. Motor function predicts parent-reported musculoskeletal pain in children with cerebral palsy. Pain Res Manag 2013;18(6):323-7. PMID 24308022
- 18
- Barth PG. Disorders of neuronal migration. Can J Neurol Sci 1987;14:1-6. PMID 3545413
- 19
- Bartlett DJ, Palisano RJ. A multivariate model of determinants of motor change for children with cerebral palsy. Phys Ther 2000;80:598-614. PMID 10842412
- 20
- Bax M, Goldstein M, Rosenbaum P, et al; Executive Committee for the Definition of Cerebral Palsy. Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol 2005;47(8):571-6. PMID 16108461
- 21
- Beckung E, Hagberg G. Neuroimpairments, activity limitations, and participation restrictions in children with cerebral palsy. Dev Med Child Neurol 2002;44:309-16. PMID 12033716
- 22
- Benini R, Shevell MI. Updates in the Treatment of Spasticity Associated With Cerebral Palsy. Curr Treat Options Neurol 2012;14(6):650-9. PMID 22851256
- 23
- Ben-Pazi H, Aran A, Pandyan A, et al. Auditory stimulation improves motor function and caretaker burden in children with cerebral palsy- a randomized double blind study. PLoS One 2018;13(12):e0208792. PMID 30543665
- 24
- Berardelli A, Rothwell JC, Hallett M, Thompson PD, Manfredi M, Marsden CD. The pathophysiology of primary dystonia. Brain 1998;121:1195-212. PMID 9679773
- 25
- Berner R. Group B streptococci during pregnancy and infancy. Curr Opin Infect Dis 2002;15:307-13. PMID 12015467
- 26
- Bertoncelli CM, Bertoncelli D, Elbaum L, et al. Validation of a clinical prediction model for the development of neuromuscular scoliosis: a multinational study. Pediatr Neurol 2018;79:14-20. PMID 29249551
- 27
- Blackman JA, Conaway MR. Adolescents with cerebral palsy: transitioning to adult health care services. Clin Pediatr (Phila) 2014;53(4):356-63. PMID 24275216
- 28
- Blair E, Stanley F. Issues in the classification and epidemiology of cerebral palsy. Ment Retard Dev Disabil Res Rev 2002;3:184-93.
- 29
- Blair EM, Nelson KB. Fetal growth restriction and risk of cerebral palsy in singletons born after at least 35 weeks' gestation. Am J Obstet Gynecol 2015;212(4):520.e1-7. PMID 25448521
- 30
- Bleck EE. Management of the lower extremities in children who have cerebral palsy. J Bone Joint Surg Am 1990;72:140-4. PMID 2404019
- 31
- Borzyskowski M. Cerebral palsy and the bladder. Dev Med Child Neurol 1989;31:682-9. PMID 2806750
- 32
- Boychuck Z, Hubermann L, Shevell M, Majnemer A. An environmental scan of current practices related to initial referral of children with cerebral palsy to medical and rehabilitation specialists. Int J Dev Neurosci 2015;47(Pt A):120-1. PMID 26531642
- 33
- Boyd R, Sakzewski L, Ziviani J, et al. INCITE: A randomised trial comparing constraint induced movement therapy and bimanual training in children with congenital hemiplegia. BMC Neurol 2010;10:4. PMID 20064275
- 34
- Brown KA, Patel DR. Complementary and alternative medicine in developmental disabilities. Indian J Pediatr 2005;72:949-52. PMID 16391450
- 35
- Brown MC, Bontempo A, Turk MA. Secondary consequences of cerebral palsy: adults with cerebral palsy in New York State. Albany, NY: Developmental Disabilities Planning Council, 1992.
- 36
- Brunelli S, Faiella A, Capra V, et al. Germline mutations in the homeobox gene EMX2 in patients with severe schizencephaly. Nat Genet 1996;12:94-6. PMID 8528262
- 37
- Brunstrom JE, Bastian AJ, Wong M, Mink JW. Motor benefit from levodopa in spastic quadriplegic cerebral palsy. Ann Neurol 2000;47:662-5. PMID 10805341
- 38
- Burdea GC, Cioi D, Kale A, Janes WE, Ross SA, Engsberg JR. Robotics and gaming to improve ankle strength, motor control and function in children with cerebral palsy-a case study series. IEEE Trans Neural Syst Rehabil Eng 2013;21(2):165-73. PMID 22773059
- 39
- Butler C, Campbell S. Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy. AACPDM Treatment Outcomes Committee Review Panel. Dev Med Child Neurol 2000;42:634-45. PMID 11034458
- 40
- Cabana MD, Crawford TO, Winkelstein JA, Christensen JR, Lederman HM. Consequences of the delayed diagnosis of ataxia-telangiectasia. Pediatrics 1998;102:98-100. PMID 9651420
- 41
- Canadian Preterm Labor Investigators Group. Treatment of preterm labor with the beta-adrenergic agonist ritodrine. N Engl J Med 1992;327:308-12. PMID 1620169
- 42
- Cao XY, Jiang XM, Dou ZH, et al. Timing of vulnerability of the brain to iodine deficiency in endemic cretinism. N Engl J Med 1994;331:1739-44. PMID 7984194
- 43
- Capparelli E, Rakhmanina N, Mirochnick M. Pharmacotherapy of perinatal HIV. Semin Fetal Neonatal Med 2005;10:161-75. PMID 15701581
- 44
- Capute AJ. Identifying cerebral palsy in infancy through study of primitive-reflex profiles. Pediatr Ann 1979;8:589-95. PMID 492783
- 45
- Capute AJ, Accardo PJ. Cerebral palsy: the spectrum of motor dysfunction. In: Capute AJ, Accardo PJ, editors. Developmental disabilities in infancy and childhood: the spectrum of developmental disabilities, II. Baltimore: Paul H Brooks Publishing, 1996:81-100.
- 46
- Carollo JJ, Heyn PC, Tagawa A, Pan Z. Aging with a physical disability: findings and implications from the Cerebral Palsy Adult Transition Study (CPAT). Innov Aging 2018;2(Suppl 1):587-8.
- 47
- Chin EM, Gorny N, Logan M, Hoon AH. Cerebral palsy and the placenta: A review of the maternal-placental-fetal origins of cerebral palsy. Exp Neurol 2022;352:114021. PMID 35196502
- 48
- Chong SK. Gastrointestinal problems in the handicapped child. Curr Opin Pediatr 2001;13:441-6. PMID 11801890
- 49
- Chrysagis N, Skordilis EK, Stavrou N, Grammatopoulou E, Koutsouki D. The effect of treadmill training on gross motor function and walking speed in ambulatory adolescents with cerebral palsy: a randomized controlled trial. Am J Phys Med Rehabil 2012;91(9):747-60. PMID 22902937
- 50
- Cioni G, Sales B, Paolicelli PB, Petacchi E, Scusa MF, Canapicchi R. MRI and clinical characteristics of children with hemiplegic cerebral palsy. Neuropediatrics 1999;30:249-55. PMID 10598836
- 51
- Clark SL, Hankins GD. Temporal and demographic trends in cerebral palsy--fact and fiction. Am J Obstet Gynecol 2003;188:628-33. PMID 12634632
- 52
- Coenen MA, Eggink H, Tijssen MA, Spikman JM. Cognition in childhood dystonia: a systematic review. Dev Med Child Neurol 2018;60(3):244-55. PMID 29238959
- 53
- Colver AF, Gibson M, Hey EN, Jarvis SN, Mackie PC, Richmond S. Increasing rates of cerebral palsy across the severity spectrum in north-east England 1964-1993. The North of England Collaborative Cerebral Palsy Survey. Arch Dis Child Fetal Neonatal Ed 2000;83:F7-12. PMID 10873162
- 54
- Coorssen EA, Msall ME, Duffy LC. Multiple minor malformations as a marker for prenatal etiology of cerebral palsy. Dev Med Child Neurol 1991;33:730-6. PMID 1916028
- 55
- Corbett MA, van Eyk CL, Webber DL, et al. Pathogenic copy number variants that affect gene expression contribute to genomic burden in cerebral palsy. NPJ Genom Med 2018;3:33. PMID 30564460
- 56
- Costantine MM, Clark EA, Lai Y, et al. Association of Polymorphisms in Neuroprotection and Oxidative Stress Genes and Neurodevelopmental Outcomes After Preterm Birth. Obstet Gynecol 2012;120(3):542-50. PMID 22914463
- 57
- Crichton JU, Mackinnon M, White CP. The life-expectancy of persons with cerebral palsy. Dev Med Child Neurol 1995;37:567-76. PMID 7615144
- 58
- Crosby AH, Proukakis C. Is the transportation highway the right road for hereditary spastic paraplegia. Am J Hum Genet 2002;71:1009-16. PMID 12355399
- 59
- Damiano DL. Early identification and intervention in developmental coordination disorder: lessons for and from cerebral palsy. Dev Med Child Neurol 2021;63(6):630. PMID 33686677
- 60
- Dammann O, Leviton A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Ped Res 1997;42(1):1-8. PMID 9212029
- 61
- Dang VM, Colver A, Dickinson HO, et al. Predictors of participation of adolescents with cerebral palsy: a European multi-centre longitudinal study. Res Dev Disabil 2014;36C:551-64. PMID 25462516
- 62
- DeLuca SC, Case-Smith J, Stevenson R, Ramey SL. Constraint-induced movement therapy (CIMT) for young children with cerebral palsy: effects of therapeutic dosage. J Pediatr Rehabil Med 2012;5(2):133-42. PMID 22699104
- 63
- De Salles AA. Role of stereotaxis in the treatment of cerebral palsy. J Child Neurol 1996;11(Suppl 1):S43-50. PMID 8959461
- 64
- Deng W, Yue Q, Rosenberg PA, Volpe JJ, Jensen FE. Oligodendrocyte excitotoxicity determined by local glutamate accumulation and mitochondrial function. J Neurochem 2006;98(1):213-22. PMID 16606353
- 65
- Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N Engl J Med 2001;344:581-90. PMID 11207355
- 66
- Dubowitz V. The Floppy Infant. 2nd Edition. Cambridge University Press, 2001.
- 67
- Dudley RW, Parolin M, Gagnon B, et al. Beneficial functional outcomes of selective dorsal rhizotomy (SDR) are long lasting and alter the natural history of motor development in spastic cerebral palsy. Neurosurgery 2012;71(2):E564-5.
- 68
- Edwards AD, Brocklehurst P, Gunn AJ, et al. Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial data. BMJ 2010;340;c363. PMID 20144981
- 69
- Egelhoff JC. MR imaging of congenital anomalies of the pediatric spine. Magn Reson Imaging Clin N Am 1999;7:459-79. PMID 10494529
- 70
- Ego C, Orban de Xivry JJ, Nassogne MC, Yuksel D, Lefevre P. Spontaneous improvement in oculomotor function of children with cerebral palsy. Res Dev Disabil 2014;36C:630-44. PMID 25462523
- 71
- Eicher DJ, Wagner CL, Katikaneni LP, et al. Moderate hypothermia in neonatal encephalopathy: efficacy outcomes. Pediatr Neurol 2005;32:11-7. PMID 15607598
- 72
- Einspieler C, Bos AF, Krieber-Tomantschger M, et al. Cerebral palsy: early markers of clinical phenotype and functional outcome. J Clin Med 2019;8(10):1616. PMID 31590221
- 73
- Emrick LT, DiCarlo SM. The expanding role of genetics in cerebral palsy. Phys Med Rehabil Clin N Am 2020;31(1):15-24. PMID 31760988
- 74
- Fabry G, Liu XC, Molenaers G. Gait pattern in patients with spastic diplegic cerebral palsy who underwent staged operations. J Pediatr Orthop 1999;8:33-8. PMID 10709595
- 75
- Ferriero DM. Neonatal brain injury. N Engl J Med 2004;351:1985-95. PMID 15525724
- 76
- Finch-Edmondson M, Morgan C, Hunt RW, Novak I. Emergent prophylactic, reparative and restorative brain interventions for infants born preterm with cerebral palsy. Front Physiol 2019;10:15. PMID 30745876
- 77
- Flenady V, Hawley G, Stock OM, Kenyon S, Badawi N. Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database Syst Rev 2013;12:CD000246. PMID 24307518
- 78
- Fong BF, De Vries JI. Obstetric aspects of the Prader-Willi syndrome. Ultrasound Obstet Gynecol 2003;21:389-92. PMID 12704750
- 79
- Forssberg H. Neural control of human motor development. Curr Opin Neurobiol 1999;9:676-82. PMID 10607646
- 80
- Franki I, Van den Broeck C, De Cat J, Molenaers G, Vanderstraeten G, Desloovere K. A study of whether video scoring is a reliable option for blinded scoring of the Gross Motor Function Measure-88. Clin Rehabil 2015;29(8):809-15. PMID 25416132
- 81
- Freud S. Infantile cerebral paralysis (1897). Russian LA, translator. Coral Gables, Florida: University of Miami Press, 1968.
- 82
- Gajdosik CG, Cicirello N. Secondary conditions of the musculoskeletal system in adolescents and adults with cerebral palsy. Phys Occup Ther Pediatr 2001;21:49-68. PMID 12043172
- 83
- Gannotti ME, Christy JB, Heathcock JC, Kolobe TH. A path model for evaluating dosing parameters for children with cerebral palsy. Phys Ther 2014;94(3):411-21. PMID 24231231
- 84
- Gilmartin R, Bruce D, Storrs BB, et al. Intrathecal baclofen for management of spastic cerebral palsy: multicenter trial. J Child Neurol 2000;15:71-7. PMID 10695888
- 85
- Glass HC, Li Y, Gardner M, et al. Early identification of cerebral palsy using neonatal MRI and general movements assessment in a cohort of high-risk term neonates. Pediatr Neurol 2021;118:20-5. PMID 33714922
- 86
- Gleeson JG, Minnerath S, Kuzniecky RI, et al. Somatic and germline mosaic mutations in the doublecortin gene are associated with variable phenotypes. Am J Hum Genet 2000;67:574-81. PMID 10915612
- 87
- Goldstein M. The treatment of cerebral palsy: What we know, what we don’t know. J Pediatr 2004;145(2 Suppl):S42-6. PMID 15292887
- 88
- Gonzalez-Mantilla PJ, Hu Y, Myers SM, et al. Diagnostic yield of exome sequencing in cerebral palsy and implications for genetic testing guidelines: a systematic review and meta-analysis. JAMA Pediatr 2023;177(5):472-8. PMID 36877506
- 89
- Gordon AM, Hung YC, Brandao M, et al. Bimanual Training and Constraint-Induced Movement Therapy in Children With Hemiplegic Cerebral Palsy: A Randomized Trial. Neurorehabil Neural Repair 2011;25(8):692-702. PMID 21700924
- 90
- Gordon C, Roopchand-Martin S, Gregg A. Potential of the Nintendo Wii™ as a rehabilitation tool for children with cerebral palsy in a developing country: a pilot study. Physiotherapy 2012;98(3):238-42. PMID 22898581
- 91
- Grether JK, Nelson KB, Cummins SK. Twinning and cerebral palsy: experience in four northern California counties, birth 1983 through 1985. Pediatrics 1993;92:854-8. PMID 8233749
- 92
- Gropman AL. Diagnosis and treatment of childhood mitochondrial diseases. Curr Neurol Neurosci Rep 2001;1:185-94. PMID 11898515
- 93
- Grunewald S, Matthijs G. Congenital disorders of glycosylation (CDG): a rapidly expanding group of neurometabolic disorders. Neuropediatrics 2000;31:57-9. PMID 10832577
- 94
- Guiffre R, Pastore FS, De Santis S. Connatal (fetal) hydrocephalus: an acquired pathology. Childs Nerv Syst 1995;11:97-101. PMID 7758019
- 95
- Gupta J, Gulati S, Singh UP, et al. Brain stimulation and constraint induced movement therapy in children with unilateral cerebral palsy: a randomized controlled trial. Neurorehabil Neural Repair 2023;37(5):266-76. PMID 37170480
- 96
- Hack M, Fanaroff AA. Outcomes of children of extremely low birth weight and gestational age in the 1990's. Early Hum Dev 1999;53:193-218. PMID 10088988
- 97
- Hadders-Algra M. Early diagnostics and early intervention in neurodevelopmental disorders-age-dependent challenges and opportunities. J Clin Med 2021;10(4):861. PMID 33669727
- 98
- Hadders-Algra M, Mavinkurve-Groothuis AM, Groen SE, Stremmelaar EF, Martijn A, Butcher PR. Quality of general movements and the development of minor neurological dysfunction at toddler and school age. Clin Rehabil 2004;18(3): 287-99. PMID 15137560
- 99
- Hagberg B, Hagberg G, Olow I, van Wendt L. The changing panorama of cerebral palsy in Sweden. VII. Prevalence and origin in the birth year period 1987-90. Acta Paediatr 1996;85:954-60. PMID 8863878
- 100
- Hagberg BA, Blennow G, Kristiansson B, Stibler H. Carbohydrate-deficient glycoprotein syndromes: peculiar group of new disorders. Pediatr Neurol 1993;9:255-62. PMID 8216537
- 101
- Hahn JS, Plawner LL. Evaluation and management of children with holoprosencephaly. Pediatr Neurol 2004;31:79-88. PMID 15301825
- 102
- Hakkarainen E, Pirilä S, Kaartinen J, van der Meere JJ. Error detection and response adjustment in youth with mild spastic cerebral palsy: an event-related brain potential study. J Child Neurol 2013;28(6):752-7. PMID 22899795
- 103
- Hallum A, Krumboltz JD. Parents caring for young adults with severe physical disabilities: psychological issues. Dev Med Child Neurol 1993;35:24-32. PMID 8449377
- 104
- Hamer EG, Bos AF, Hadders-Algra M. Assessment of specific characteristics of abnormal general movements: does it enhance the prediction of cerebral palsy. Dev Med Child Neurol 2011;53(8):751-6. PMID 21711457
- 105
- Hansel DE, Hansel CR, Shindle MK, et al. Oral baclofen in cerebral palsy: Possible seizure potentiation. Pediatr Neurol 2003;29(3):203-6. PMID 14629901
- 106
- Harada T, Ebara S, Anwar MM, et al. The cervical spine in athetoid cerebral palsy: a radiological study of 180 patients. J Bone Joint Surg Br 1996;78:613-9. PMID 8682830
- 107
- Harum KH, Hoon AH Jr, Casella JF. Factor-V Leiden: a risk factor for cerebral palsy. Dev Med Child Neurol 1999;41:781-5. PMID 10576643
- 108
- Haseltine F, Cole SS, Gray DB, editors. Reproductive issues for persons with physical disabilities. Baltimore: Paul H Brooks, 1993.
- 109
- Hayward JC, Titelbaum DS, Clancy RR, Zimmerman RA. Lissencephaly-pachygyria associated with congenital cytomegalovirus infection. J Child Neurol 1991;6:109-14. PMID 1646253
- 110
- Heidenreich R, Natowicz M, Hainline BE, et al. Acute extrapyramidal syndrome in methylmalonic academia: 'metabolic stroke' involving the globus pallidus. J Pediatr 1988;113:1022-27. PMID 3193307
- 111
- Hilderley AJ, Fehlings D, Lee GW, Wright FV. Comparison of a robotic-assisted gait training program with a program of functional gait training for children with cerebral palsy: design and methods of a two group randomized controlled cross-over trial. Springerplus 2016;5(1):1886. PMID 27843743
- 112
- Hirtz DG, Weiner SJ, Bulas D, et al. Antenatal magnesium and cerebral palsy in preterm infants. J Pediatr 2015;167(4):834-9. PMID 26254839
- 113
- Hollegaard MV, Skogstrand K, Thorsen P, Nørgaard-Pedersen B, Hougaard DM, Grove J. Joint analysis of SNPs and proteins identifies regulatory IL18 gene variations decreasing the chance of spastic cerebral palsy. Hum Mutat 2013;34(1):143-8. PMID 22837141
- 114
- Hoon AH, Belsito KM, Nagae-Poetscher LM. Neuroimaging in spasticity and movement disorders. J Child Neurol 2003;18:S25-39. PMID 13677569
- 115
- Hoon AH, Freese PO, Reinhardt EM, et al. Age dependent beneficial effects of trihexyphenidyl in children with extrapyramidal cerebral palsy. Ped Neurol 2001;25:55-8. PMID 11483397
- 116
- Hoon AH, Johnston MV. Cerebral palsy. In: Asbury AK, McKhann GM, McDonald WI, et al, editors. Diseases of the nervous system: clinical neuroscience and therapeutic principles. Cambridge: Cambridge University Press, 2002:568-85.
- 117
- Hoon AH, Lawrie WT, Melhem E, et al. Diffusion tensor imaging of PVL shows affected sensory cortex white matter pathways. Neurology 2002;59:752-6. PMID 12221171
- 118
- Hoon AH, Melhem ER. Neuroimaging: applications in disorders of early brain development. J Dev Behav Pediatr 2000;21:291-302. PMID 10972254
- 119
- Hoon AH, Reinhardt EM, Kelley RI, et al. Brain MR imaging in suspected extrapyramidal cerebral palsy: observations in distinguishing genetic-metabolic from acquired etiologies. J Pediatr 1997;131:240-5. PMID 9290610
- 120
- Horwood L, Li P, Mok E, Shevell M, Constantin E. A systematic review and meta-analysis of the prevalence of sleep problems in children with cerebral palsy: how do children with cerebral palsy differ from each other and from typically developing children? Sleep Health 2019;5(6):555-71. PMID 31740377
- 121
- Huppi PS, Murphy B, Maier SE, et al. Microstructural brain development after perinatal cerebral white matter injury assessed by diffusion tensor magnetic resonance imaging. Pediatrics 2001;107:455-60. PMID 11230582
- 122
- Hyrapetian M, Loucaides EM, Sutcliffe AG. Health and disease in children born after assistive reproductive therapies (ART). J Reprod Immunol 2014;106:21-6. PMID 25438931
- 123
- Inder T, Huppi PS, Zientara GP, et al. Early detection of periventricular leukomalacia by diffusion-weighted magnetic resonance imaging techniques. J Pediatr 1999;134:631-4. PMID 10228300
- 124
- Inguaggiato E, Bolognini N, Fiori S, Cioni G. Transcranial direct current stimulation (tDCS) in unilateral cerebral palsy: a pilot study of motor effect. Neural Plast 2019;2019:2184398. PMID 30733800
- 125
- Ishida C, Fujiita M, Umemoto H, Taneda M, Sanae N, Tazaki T. Respiratory function in handicapped children. Brain Dev 1990;12:372-5. PMID 2146900
- 126
- Ito T, Tanikawa M, Miura H, et al. The movements of fetuses with congenital myotonic dystrophy in utero. J Perinat Med 1996;24:277-82. PMID 8827577
- 127
- Jacobsson B, Hagberg G. Antenatal risk factors for cerebral palsy. Best Pract Res Clin Obstet Gynaecol 2004;18(3):425-36. PMID 15183137
- 128
- Jang DH, Sung IY, Kang YJ. Usefulness of the Tendon Reflex for Assessing Spasticity After Botulinum Toxin-A Injection in Children With Cerebral Palsy. J Child Neurol 2013;28(1):21-6. PMID 22832767
- 129
- Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988;38:391-4. PMID 3279337
- 130
- Jin SC, Lewis SA, Bakhtiari S, et al. Mutations disrupting neuritogenesis genes confer risk for cerebral palsy. Nat Genet 2020;52(10):1046-56. PMID 32989326
- 131
- Johnson AJ, Lee BC, Lin W. Echoplanar diffusion-weighted imaging in neonates and infants with suspected hypoxic-ischemic injury: correlation with patient outcome. AJR Am J Roentgenol 1999;172:219-26. PMID 9888771
- 132
- Johnston MV. Can a mother's infection damage her baby's brain. Neuro Net Comm 1998a:305-11.
- 133
- Johnston MV. Selective vulnerability of the neonatal brain. Ann Neurol 1998b;44:155-6. PMID 9708534
- 134
- Johnston MV, Fatemi A, Wilson MA, Northington F. Treatment advances in neonatal neuroprotection and neurointensive care. Lancet Neurol 2011;10(4):372-82. PMID 21435600
- 135
- Johnston MV, Hoon AH. Excitotoxicity and patterns of brain injury from fetal or perinatal asphyxia. In: Maulik D, editor. Asphyxia and fetal brain damage. New York: Wiley-Liss, 1998:113-25.
- 136
- Johnston MV, Hoon AH. Cerebral palsy. Neuromolecular Med 2006;8(4):435-50. PMID 17028368
- 137
- Juul SE, Comstock BA, Wadhawan R, et al. A randomized trial of erythropoietin for neuroprotection in preterm infants. N Engl J Med 2020;382(3):233-43. PMID 31940698
- 138
- Kennes J, Rosenbaum P, Hanna SE, et al. Health status of school-aged children with cerebral palsy: information from a population-based sample. Dev Med Child Neurol 2002;44:240-7. PMID 11995892
- 139
- Keogh JM, Badawi N, Kurinczuk JJ, Dixon G, Jongeling B, Stanley FJ. Maternal awareness of fetal seizures in pregnancies resulting in newborn encephalopathy. Acta Obstet Gynecol Scand 2000;79:787-9. PMID 10993104
- 140
- Kim JP, Chang WS, Cho SR, Chang JW. The Effect of Bilateral Globus Pallidus Internus Deep Brain Stimulation plus Ventralis Oralis Thalamotomy on Patients with Cerebral Palsy. Stereotact Funct Neurosurg 2012;90(5):292-299. PMID 22797720
- 141
- Kingsnorth S, Orava T, Provvidenza C, et al. Chronic pain assessment tools for cerebral palsy: a systematic review. Pediatrics 2015;136(4):e947-60. PMID 26416940
- 142
- Klingels K, Meyer S, Mailleux L, et al. Time course of upper limb function in children with unilateral cerebral palsy: a five-year follow-up study. Neural Plast 2018;2018:2831342. PMID 30538737
- 143
- Kobayashi H, Garcia CA, Alfonso G, et al. Molecular genetics of familial spastic paraplegia: a multitude of responsible genes. J Neurol Sci 1996;137:131-8. PMID 8782167
- 144
- Koman LA, Mooney JF, Smith BP, Walker F, Leon JM. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. J Pediatr Orthop 2000;20:108-15. PMID 10641699
- 145
- Korf BR. The hereditary dystonias: an emerging story with a twist. Ann Neurol 1998;44:4-5. PMID 9667585
- 146
- Krotoski DM, Nosek MA, Turk MA, editors. Women with physical disabilities: achieving and maintaining health and well-being. Baltimore: Paul H Brooks, 1997.
- 147
- Kuban KC, Leviton A. Cerebral palsy. N Engl J Med 1994;330:188-95. PMID 8264743
- 148
- Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999;340:9-13. PMID 9878639
- 149
- Kurz MJ, Heinrichs-Graham E, Arpin DJ, Becker KM, Wilson TW. Aberrant synchrony in the somatosensory cortices predicts motor performance errors in children with cerebral palsy. J Neurophysiol 2014;111(3):573-9. PMID 24225536
- 150
- Lally PJ, Montaldo P, Oliveira V, et al. Magnetic resonance spectroscopy assessment of brain injury after moderate hypothermia in neonatal encephalopathy: a prospective multicentre cohort study. Lancet Neurol 2019;18(1):35-45. PMID 30447969
- 151
- Landes SD, Stevens JD, Turk MA. Postmortem diagnostic overshadowing: reporting cerebral palsy on death certificates. J Health Soc Behav 2022;63(4):525-42. PMID 35266426
- 152
- Latash ML, Penn RD. Changes in voluntary motor control induced by intrathecal baclofen in patients with spasticity of different etiology. Physiother Res Int 1996;1:229-46. PMID 9238740
- 153
- Leach EL, Shevell M, Bowden K, Stockler-Ipsiroglu S, van Karnebeek C. Treatable inborn errors of metabolism presenting as cerebral palsy mimics: systematic literature review. Orphanet J Rare Dis 2014;9:197. PMID 25433678
- 154
- Lee J, Croen LA, Backstrand KH, et al. Maternal and infant characteristics associated with perinatal arterial stroke in the infant. JAMA 2005;293:723-9. PMID 15701914
- 155
- Lee RW, Poretti A, Cohen JS, et al. A diagnostic approach for cerebral palsy in the genomic era. Neuromolecular Med 2014;16(4):821-44. PMID 25280894
- 156
- Lenti C, Bianchini E. Neuropsychological and neuroradiological study of a case of early-onset Huntington's chorea. Devlop Med Child Neurol 1993;35:1007-10. PMID 8224553
- 157
- Lequin MH, Barkovich AJ. Current concepts of cerebral malformation syndromes. Curr Opin Pediatr 1999;11:492-6. PMID 10590905
- 158
- Letzkus L, Fehlings D, Ayala L, et al. A systematic review of assessments and interventions for chronic pain in young children with or at high risk for cerebral palsy. J Child Neurol 2021;36(9):697-710. PMID 33719661
- 159
- Leviton A, Allred EN, Kuban KC, et al. Microbiologic and histologic characteristics of the extremely preterm infant's placenta predict white matter damage and later cerebral palsy. The ELGAN study. Pediatr Res 2010;67(1):95-101. PMID 19745780
- 160
- Leviton A, Dammann O. Maternal intrauterine infection, cytokines and brain damage in the preterm newborn. Pediatr Res 1997;42:1-8. PMID 9212029
- 161
- Lins LAB, Nechyporenko AV, Halanski MA, Hetzel SJ, Noonan KJ. Does an intrathecal baclofen pump impact scoliosis progression and complicate posterior spine fusion in patients with cerebral palsy? Spine Deform 2020;8(1):115-21. PMID 31981152
- 162
- Liow NY, Gimeno H, Lumsden DE, et al. Gabapentin can significantly improve dystonia severity and quality of life in children. Eur J Paediatr Neurol 2016;20(1):100-7. PMID 26455274
- 163
- Liptak GS. Complementary and alternative therapies for cerebral palsy. Ment Retard Dev Disabil Res Rev 2005;11(2):156-63. PMID 15977320
- 164
- Little WJ. On the influence of abnormal parturition, difficult labour, premature birth, and asphyxia neonatorum on the mental and physical conditions of the child, especially in relation to deformities. Trans Obstet Soc Lond 1861;3:293-344.
- 165
- Ma SR, Choi JB. Effect of electrical stimulation on aspiration in children with cerebral palsy and dysphagia. J Phys Ther Sci 2019;31(1):93-4. PMID 30774213
- 166
- Maciver D, Rutherford M, Arakelyan S, et al. Participation of children with disabilities in school: a realist systematic review of psychosocial and environmental factors. PLoS One 2019;14(1):e0210511. PMID 30695082
- 167
- Marcström A, Hägglund G, Alriksson-Schmidt AI. Hip pain in children with cerebral palsy: a population-based registry study of risk factors. BMC Musculoskelet Disord 2019;20(1):62. PMID 30736784
- 168
- Marcus S, Friedman JN, Lacombe-Duncan A, Mahant S. Neuromuscular electrical stimulation for treatment of dysphagia in infants and young children with neurological impairment: a prospective pilot study. BMJ Paediatr Open 2019;3(1):e000382. PMID 30740545
- 169
- Margolis RL. The spinocerebellar ataxias: order emerges from chaos. Curr Neurol Neurosci Rep 2002;2:447-56. PMID 12169226
- 170
- Marlow N, Wolke D, Bracewell MA, Samara M; EPICure Study Group. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med 2005;352:9-19. PMID 15635108
- 171
- Marquardt T, Denecke J. Congenital disorders of glycosylation: review of their molecular bases, clinical presentations and specific therapies. Eur J Pediatr 2003;162:359-79. PMID 12756558
- 172
- Martins E, Cordovil R, Oliveira R, et al. Efficacy of suit therapy on functioning in children and adolescents with cerebral palsy: a systematic review and meta-analysis. Dev Med Child Neurol 2016;58(4):348-60. PMID 26613800
- 173
- Mei C, Reilly S, Reddihough D, Mensah F, Pennington L, Morgan A. Language outcomes of children with cerebral palsy aged 5 years and 6 years: a population-based study. Dev Med Child Neurol 2016;58(6):605-11. PMID 26566585
- 174
- Mercuri E, Cowan F, Gupte G, et al. Prothrombotic disorders and abnormal neurodevelopmental outcome in infants with neonatal cerebral infarction. Pediatrics 2001;107:1400-4. PMID 11389264
- 175
- Miller G. Cerebral palsies. In: Miller G, Ramer JR, editors. Static Encephalopathies of Infancy and Childhood. New York: Raven, 1992:11-26.
- 176
- Miller SP, Shevell MI, Patenaude Y, O’Gorman AM. Neuromotor spectrum of periventricular leukomalacia in children born at term. Ped Neurol 2000;23(2):155-9. PMID 11020641
- 177
- Mitchell W. Neurologic and developmental effects of HIV and AIDS in children and adolescents. Ment Retard Dev Disabil Res Rev 2001;7:211-6. PMID 11553937
- 178
- Moreno-De-Luca A, Millan F, Pesacreta DR, et al. Molecular diagnostic yield of exome sequencing in patients with cerebral palsy. JAMA 2021;325(5):467-75. PMID 33528536
- 179
- Mori S, Crain BJ, Chacko VP, van Zijl PC. Three-dimensional tracking of axonal projections in the brain by magnetic imaging. Ann Neurol 1999;45:265-9. PMID 9989633
- 180
- Morioka C, Komaki M, Taki A, et al. Neuroprotective effects of human umbilical cord-derived mesenchymal stem cells on periventricular leukomalacia-like brain injury in neonatal rats. Inflamm Regen 2017;37:1. PMID 29259700
- 181
- Morrell DS, Pearson JM, Sauser DD. Progressive bone and joint abnormalities of the spine and lower extremities in cerebral palsy. Radiographics 2002;22:257-68. PMID 11896216
- 182
- Morton DH, Bennett MJ, Seargeant LE, Nichter CA, Kelley RI. Glutaric aciduria type I: a common cause of episodic encephalopathy and spastic paralysis in the Amish of Lancaster County, Pennsylvania. Am J Med Genet 1991;41:89-95. PMID 1951469
- 183
- Msall ME. Complexity of the cerebral palsy syndromes: toward a developmental neuroscience approach. JAMA 2006;296(13):1650-2. PMID 17018809
- 184
- Murphy CC, Yeargin-Allsopp M, Decoufle P, Drews CD. Prevalence of cerebral palsy among ten-year-old children in metropolitan Atlanta, 1985 through 1987. J Pediatr 1993;123:S13-20. PMID 8229472
- 185
- Nance E, Porambo M, Zhang F, et al. Systemic dendrimer-drug treatment of ischemia-induced neonatal white matter injury. J Control Release 2015;214:112-20. PMID 26184052
- 186
- Nelson KB. Prenatal origin of hemiparetic cerebral palsy: how often and why. Pediatrics 1991;88:1059-61. PMID 1945614
- 187
- Nelson KB. The neurologically impaired child and alleged malpractice at birth. Neurol Clin 1999;17:283-93. PMID 10196409
- 188
- Nelson KB. The epidemiology of cerebral palsy in term infants. Ment Retard Dev Disabil Res Rev 2002;8:146-50. PMID 12216058
- 189
- Nelson KB, Blair E. Prenatal factors in singletons with cerebral palsy born at or near term. N Engl J Med 2015;373(10):946-53. PMID 26332549
- 190
- Nelson KB, Dambrosia JM, Grether JK, Phillips TM. Neonatal cytokines and coagulation factors in children with cerebral palsy. Ann Neurol 1998;44:665-75. PMID 9778266
- 191
- Nelson KB, Ellenberg JH. Children who “outgrew” cerebral palsy. Pediatrics 1982;69:529-36. PMID 7079007
- 192
- Nelson KB, Ellenberg JH. Antecedents of cerebral palsy: multivariate analysis of risk. N Engl J Med 1986;315:81-6. PMID 3724803
- 193
- Nolan J, Chalkiadis GA, Low J, Olesch CA, Brown TC. Anaesthesia and pain management in cerebral palsy. Anaesthesia 2000;55:32-41. PMID 10594431
- 194
- Novotny E, Ashwal S, Shevell M. Proton magnetic resonance spectroscopy: an emerging technology in pediatric neurology research. Ped Res 1998;44:1-10. PMID 9667363
- 195
- Nygaard TG, Waran SP, Levine RA, Naini AB, Chutorian AM. Dopa-responsive dystonia simulating cerebral palsy. Pediatr Neurol 1994;11:236-40. PMID 7880338
- 196
- Obeid R, Chang T, Bluth E, et al. The use of clinical examination and cranial ultrasound in the diagnosis and management of post-hemorrhagic ventricular dilation in extremely premature infants. J Perinatol 2018;38(4):374-80. PMID 29255191
- 197
- Oh MY, Abosch A, Kim SH, Lang AE, Lozano AM. Long-term hardware-related complications of deep brain stimulation. Neurosurgery 2002;50:1268-74. PMID 12015845
- 198
- Oishi K, Faria AV, Yoshida S, Chang L, Mori S. Reprint of "Quantitative evaluation of brain development using anatomical MRI and diffusion tensor imaging". Int J Dev Neurosci 2014;32:28-40. PMID 24295553
- 199
- Oka A, Belliveau MJ, Rosenberg PA, Volpe JJ. Vulnerability of oligodendroglia to glutamate: pharmacology, mechanisms, and prevention. J Neurosci 1993;13:1441-53. PMID 8096541
- 200
- Opitz JM, Gilbert-Barness E, Ackerman J, Lowichik A. Cholesterol and development: the RSH ("Smith-Lemli-Opitz") syndrome and related conditions. Pediatr Pathol Mol Med 2002;21:153-81. PMID 11942534
- 201
- O’Shea TM. Cerebral palsy in very preterm infants: new epidemiological insights. Ment Retard Dev Disabil Res Rev 2002;8:135-45. PMID 12216057
- 202
- Osler W. The cerebral palsies of children (1889). London: Mac Keith Press, 1987.
- 203
- Parer JT, King T. Fetal heart rate monitoring: is it salvageable. Am J Obstet Gynecol 2000;182:982-7. PMID 10764485
- 204
- Parikh NA. Advanced neuroimaging and its role in predicting neurodevelopmental outcomes in very preterm infants. Semin Perinatol 2016;40(8):530-41. PMID 27863706
- 205
- Parikh NA, Kennedy KA, Lasky RE, Tyson JE. Neurodevelopmental outcomes of extremely preterm infants randomized to stress dose hydrocortisone. PLoS One 2015;10(9):e0137051. PMID 26376074
- 206
- Patane L, Ghidini A. Fetal seizures: case report and literature review. J Matern Fetal Med 2001;10:287-9. PMID 11531157
- 207
- Paton MCB, Finch-Edmondson M, Fahey MC, London J, Badawi N, Novak I. Fifteen years of human research using stem cells for cerebral palsy: a review of the research landscape. J Paediatr Child Health 2021;57(2):295-6. PMID 33600635
- 208
- Pearl PL, Wallis DD, Gibson KM. Pediatric neurotransmitter disorders. Curr Neurol Neurosci Rep 2004;4:147-52. PMID 14984687
- 209
- Penn RD, Kroin JS. Continuous intrathecal baclofen for severe spasticity. Lancet 1985;2(8447):125-7. PMID 2862320
- 210
- Perlman JM, Volpe JJ. Movement disorder of premature infants with severe bronchopulmonary dysplasia: a new syndrome. Pediatrics 1989;84:215-8. PMID 2748247
- 211
- Petersen MC, Kube DA, Palmer FB. Classification of developmental delays. Semin Pediatr Neurol 1998;5:2-14. PMID 9548635
- 212
- Peterson MD, Ryan JM, Hurvitz EA, Mahmoudi E. Chronic conditions in adults with cerebral palsy. JAMA 2015;314(21):2303-5. PMID 26624831
- 213
- Peterson MD, Wilson AM, Hurvitz EA. Underlying causes of death among adults with cerebral palsy. J Clin Med 2022;11(21):6333. PMID 36362560
- 214
- Petterson B, Nelson KB, Watson L, Stanley F. Twins, triplets, and cerebral palsy in births in Western Australia in the 1980's. BMJ 1993;307(6914):1239-43. PMID 8281055
- 215
- Peyton C, Yang E, Msall ME, et al. White matter injury and general movements in high-risk preterm infants. AJNR Am J Neuroradiol 2017;38(1):162-9. PMID 27789448
- 216
- Pinero JR, Goldstein RY, Culver S, Kuhns CA, Feldman DS, Otsuka NY. Hip flexion contracture and diminished functional outcomes in cerebral palsy. J Pediatr Orthop 2012;32(6):600-4. PMID 22892622
- 217
- Polin RA, Harris MC. Neonatal bacterial meningitis. Semin Neonatol 2001;6(2):157-72. PMID 11483021
- 218
- Pranzatelli MR. Oral pharmacotherapy for the movement disorders of cerebral palsy. J Child Neurol 1996;11(Suppl 1):S13-22. PMID 8959457
- 219
- Prasad AN, Breen JC, Ampola MG, Rosman NP. Argininemia: a treatable genetic cause of progressive spastic diplegia simulating cerebral palsy: case reports and literature review. J Child Neurol 1997;12:301-9. PMID 9378897
- 220
- Prechtl HF, Einspieler C, Cioni G, Bos AF, Ferrari F, Sontheimer D. An early marker for neurological deficits after perinatal brain lesions. Lancet 1997;349(9062):1361-3. PMID 9149699
- 221
- Prosser LA, Ohlrich LB, Curatalo LA, Alter KE, Damiano DL. Feasibility and preliminary effectiveness of a novel mobility training intervention in infants and toddlers with cerebral palsy. Dev Neurorehabil 2012;15(4):259-66. PMID 22670679
- 222
- Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society, Delgado MR, Hirtz D, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2010;74(4):336-43. PMID 20101040
- 223
- Ramey SL, DeLuca S, Stevenson RD, Case-Smith J, Darragh A, Conaway M. Children with Hemiparesis Arm and Movement Project (CHAMP): protocol for a multisite comparative efficacy trial of paediatric constraint-induced movement therapy (CIMT) testing effects of dosage and type of constraint for children with hemiparetic cerebral palsy. BMJ Open 2019;9(1):e023285. PMID 30782701
- 224
- Rasmussen HM, Nordbye-Nielsen K, Møller-Madsen B, et al. The Danish Cerebral Palsy Follow-up Program. Clin Epidemiol 2016;8:457-60. PMID 27822084
- 225
- Razak A, Johnston E, Sackett V, et al. Early neurodevelopmental assessments for predicting long-term outcomes in infants at high risk of cerebral palsy. JAMA Netw Open 2024;7(5):e2413550. PMID 38709738
- 226
- Rempel G. The importance of good nutrition in children with cerebral palsy. Phys Med Rehabil Clin N Am 2015;26(1):39-56. PMID 25479778
- 227
- Rogers B. Feeding method and health outcomes of children with cerebral palsy. J Pediatr 2004;145(2 Suppl):S28-32. PMID 15292884
- 228
- Rogers EE, Bonifacio SL, Glass HC, et al. Erythropoietin and hypothermia for hypoxic-ischemic encephalopathy. Pediatr Neurol 2014;51(5):657-62. PMID 25439577
- 229
- Rogers EE, Hintz SR. Early neurodevelopmental outcomes of extremely preterm infants. Semin Perinatol 2016;40(8):497-509. PMID 27865437
- 230
- Romito LM, Zorzi G, Marras CE, Franzini A, Nardocci N, Albanese A. Pallidal stimulation for acquired dystonia due to cerebral palsy: beyond 5 years. Eur J Neurol 2015;22(3):426-e32. PMID 25382808
- 231
- Rosenstein NE, Perkins BA. Update on Haemophilus influenzae serotype b and meningococcal vaccines. Pediatr Clin North Am 2000;47:337-52, vi. PMID 10761507
- 232
- Rossi A, Cama A, Piatelli G, Ravegnani M, Biancheri R, Tortori-Donati P. Spinal dysraphism: MR imaging rationale. J Neuroradiol 2004;31:3-24. PMID 15026728
- 233
- Russman BS, Ashwal S. Evaluation of the child with cerebral palsy. Semin Pediatr Neurol 2004;11:47-57. PMID 15132253
- 234
- Ryan JM, Albairami F, Hamilton T, et al. Prevalence and incidence of chronic conditions among adults with cerebral palsy: A systematic review and meta-analysis. Dev Med Child Neurol 2023. [Epub ahead of print] PMID 36807150
- 235
- Saint Hilaire MH, Burke RE, Bressman SB, Brin MF, Fahn S. Delayed-onset dystonia due to perinatal or early childhood asphyxia. Neurology 1991;41:216-22. PMID 1992364
- 236
- Sakzewski L, Provan K, Ziviani J, Boyd RN. Comparison of dosage of intensive upper limb therapy for children with unilateral cerebral palsy: how big should the therapy pill be? Res Dev Disabil 2015;37:9-16. PMID 25460215
- 237
- Sakzewski L, Ziviani J, Abbott DF, Macdonell RA, Jackson GD, Boyd RN. Equivalent retention of gains at 1 year after training with constraint-induced or bimanual therapy in children with unilateral cerebral palsy. Neurorehabil Neural Repair 2011;25(7):664-71. PMID 21427273
- 238
- Sampson D, Pickard M, Evans I, Leonard A, Sinha A, Ekins R. Thyroid hormone regulates the expression of alpha-internexin in neurons in culture. Neuroreport 2002;13:273-7. PMID 11930121
- 239
- Sanger T. Dystonia. WebSite:WE MOVE - Dystonia, Cervical Dystonia, and Pediatric Forms of Dystonia. Accessed 2002.
- 240
- Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW; Task Force on Childhood Motor Disorders. Classification and definition of disorders causing hypertonia in childhood. Pediatrics 2003;111:e89-97. PMID 12509602
- 241
- Scheller JM, Nelson KB. Does cesarean delivery prevent cerebral palsy or other neurologic problems of childhood. Obstet Gynecol 1994;83:624-30. PMID 8134078
- 242
- Schendel DE, Schuchat A, Thorsen P. Public health issues related to infection in pregnancy and cerebral palsy. Ment Retard Dev Disabil Res Rev 2002;8:39-45. PMID 11921385
- 243
- Scott BL, Jankovic J. Delayed-onset progressive movement disorders after static brain lesions. Neurology 1996;46:68-74. PMID 8559423
- 244
- Sellier E, Platt MJ, Andersen GL, et al. Decreasing prevalence in cerebral palsy: a multi-site European population-based study, 1980 to 2003. Dev Med Child Neurol 2016;58(1):85-92. PMID 26330098
- 245
- Serenius F, Källén K, Blennow M, et al. Neurodevelopmental outcome in extremely preterm infants at 2.5 years after active perinatal care in Sweden. JAMA 2013;309(17):1810-20. PMID 23632725
- 246
- Shankaran S, Pappas A, McDonald SA, et al. Childhood outcomes after hypothermia for neonatal encephalopathy. N Engl J Med 2012;366(22):2085-92. PMID 22646631
- 247
- Shapiro BK. Cerebral palsy: A reconceptualization of the spectrum. J Pediatr 2004;145(2 Suppl):S3-7. PMID 15292880
- 248
- Shu SK, Ashwal S, Holshouser BA, Nystrom G, Hinshaw DB Jr. Prognostic value of 1H-MRS in perinatal CNS insults. Pediatr Neurol 1997;17:309-18. PMID 9436794
- 249
- Siddiqi SU, Van Dyke DC, Donohoue P, McBrien DM. Premature sexual development in individuals with neurodevelopmental disabilities. Dev Med Child Neurol 1999;41:392-5. PMID 10400173
- 250
- Skalsky AJ, Fournier CM. Intrathecal baclofen bolus dosing and catheter tip placement in pediatric tone management. Phys Med Rehabil Clin N Am 2015;26(1):89-93. PMID 25479782
- 251
- Soul JS, Robertson RL, Tzika AA, et al. Time course of changes in diffusion-weighted magnetic resonance imaging in a case of neonatal encephalopathy with defined onset and duration of hypoxic-ischemic insult. Pediatrics 2001;108(5):1211-4. PMID 11694704
- 252
- Srivastava S, Lewis SA, Cohen JS, et al. Molecular diagnostic yield of exome sequencing and chromosomal microarray in cerebral palsy: a systematic review and meta-analysis. JAMA Neurol 2022;79(12):1287-95. PMID 36279113
- 253
- Stevenson CJ, Pharoah PO, Stevenson R. Cerebral palsy--the transition from youth to adulthood. Dev Med Child Neurol 1997;39:336-42. PMID 9236701
- 254
- Strauss D, Cable W, Shavelle R. Causes of excess mortality in cerebral palsy. Dev Med Child Neurol 1999;41:580-5. PMID 10503915
- 255
- Strauss DJ, Shavelle RM, Anderson TW. Life expectancy of children with cerebral palsy. Pediatr Neurol 1998;18:143-9. PMID 9535300
- 256
- Sugiura T, Goto T, Ueda H, et al. Periventricular leukomalacia is decreasing in Japan. Pediatr Neurol 2012;47(1):35-9. PMID 22704014
- 257
- Surveillance of Cerebral Palsy in Europe. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Dev Med Child Neurol 2000;42:816-24. PMID 11132255
- 258
- Takanashi J, Barkovich AJ, Ferriero DM, Suzuki H, Kohno Y. Widening spectrum of congenital hemiplegia: Periventricular venous infarction in term neonates. Neurology 2003;61:531-3. PMID 12939430
- 259
- Thom EA, Rouse DJ; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. What we have learned about conducting randomized controlled trials in the NICHD MFMU network. Semin Perinatol 2003;27:253-60. PMID 12889593
- 260
- Thomason P, Selber P, Graham HK. Single Event Multilevel Surgery in children with bilateral spastic cerebral palsy: A 5 year prospective cohort study. Gait Posture 2013;37(1):23-8. PMID 22818117
- 261
- Thorarensen O, Ryan S, Hunter J, Younkin DP. Factor V Leiden mutation: an unrecognized cause of hemiplegic cerebral palsy, neonatal stroke, and placental thrombosis. Ann Neurol 1997;42:372-5. PMID 9307261
- 262
- Tilton AH, Sanders JS. The changing face of cerebral palsy. Ann Neurol 2021;89(5):858-9. PMID 33650158
- 263
- Trevarrow MP, Reelfs A, Baker SE, Hoffman RM, Wilson TW, Kurz MJ. Spinal cord microstructural changes are connected with the aberrant sensorimotor cortical oscillatory activity in adults with cerebral palsy. Sci Rep 2022;12(1):4807. PMID 35314729
- 264
- Turk MA, Scandale J, Rosenbaum PF, Weber RJ. The health of women with cerebral palsy. Phys Med Rehabil Clin N Am 2001;12:153-68. PMID 11853034
- 265
- US Department of Health and Human Services. Healthy people 2010: understanding and improving health. 2nd edition. Washington DC: US Department of Health and Human Services, 2000.
- 266
- Utiger RD. Maternal hypothyroidism and fetal development. N Engl J Med 1999;341:601-2. PMID 10451467
- 267
- Verrall CE, Walker K, Loughran-Fowlds A, et al. Contemporary incidence of stroke (focal infarct and/or haemorrhage) determined by neuroimaging and neurodevelopmental disability at 12 months of age in neonates undergoing cardiac surgery utilizing cardiopulmonary bypass. Interact Cardiovasc Thorac Surg 2018;26(4):644-50. PMID 29228213
- 268
- Vogels A, Fryns JP. The Prader-Willi syndrome and the Angelman syndrome. Genet Couns 2002;13:385-96. PMID 12558108
- 269
- Volpe JJ. Neurology of the newborn. 4th ed. Philadelphia: WB Saunders Co, 2001a.
- 270
- Volpe JJ. Neurobiology of periventricular leukomalacia in the premature infant. Pediatr Res 2001b;50(5):553-62. PMID 11641446
- 271
- von Kleist-Retzow JC, Cormier-Daire V, Viot G, et al. Antenatal manifestations of mitochondrial respiratory chain deficiency. J Pediatr 2003;143:208-12. PMID 12970634
- 272
- Wallace SJ. Epilepsy in cerebral palsy. Dev Med Child Neurol 2001;43:713-7. PMID 11665830
- 273
- Watts JL, Saigal S. Outcome of extreme prematurity: as information increases so do the dilemmas. Arch Dis Child Fetal Neonatal Ed 2006;91:F221-5. PMID 16632651
- 274
- Willemsen MA, IJlst L, Steijlen PM, et al. Clinical, biochemical and molecular genetic characteristics of 19 patients with the Sjogren-Larsson syndrome. Brain 2001;124:1426-37. PMID 11408337
- 275
- Williams CA. Neurological aspects of Angelman syndrome. Brain Dev 2005;27:88-94. PMID 15668046
- 276
- Williams SA, Elliott C, Valentine J, Gubbay A, Shipman P, Reid S. Combining strength training and botulinum neurotoxin intervention in children with cerebral palsy: the impact on muscle morphology and strength. Disabil Rehabil 2013;35(7):596-605. PMID 22928803
- 277
- Wilson JL, Kim YM, O'Malley JA, et al. Cerebral palsy in child neurology and neurodevelopmental disabilities training: an unmet need. J Child Neurol 2022;37(3):194-201. PMID 35037781
- 278
- Wilson-Costello D, Friedman H, Minich N, Fanaroff AA, Hack M. Improved survival rates with increased neurodevelopmental disability for extremely low birth weight infants in the 1990s. Pediatrics 2005;115(4):997-1003. PMID 15805376
- 279
- Winch R, Bengtson L, McLaughlin J, Fitzsimmons J, Budden S. Women with cerebral palsy: obstetric experience and neonatal outcome. Dev Med Child Neurol 1993;35:974-82. PMID 8224564
- 280
- Wissel J, Heinen F, Schenkel A, et al. Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of "high-dose" versus "low-dose" treatment. Neuropediatrics 1999;30:120-4. PMID 10480205
- 281
- Wood E, Rosenbaum P. The gross motor function classification system for cerebral palsy: a study of reliability and stability over time. Dev Med Child Neurol 2000;42:292-6. PMID 10855648
- 282
- Wright PA, Durham S, Ewins DJ, Swain ID. Neuromuscular electrical stimulation for children with cerebral palsy: a review. Arch Dis Child 2012;97(4):364-71. PMID 22447997
- 283
- Wu YW, Mehravari AS, Numis AL, Gross P. Cerebral palsy research funding from the National Institutes of Health, 2001 to 2013. Dev Med Child Neurol 2015;57(10):936-41. PMID 25951080
- 284
- Yeargin-Allsopp M, Van Naarden Braun K, Doernberg NS, Benedict RE, Kirby RS, Durkin MS. Prevalence of cerebral palsy in 8-year-old children in three areas of the United States in 2002: a multisite collaboration. Pediatrics 2008;121(3):547-54. PMID 18310204
- 285
- Zhang HY, Du F. [Clinical trials of acupuncture intervention combined with sitting training for cerebral palsy children with parafunctional sitting position]. Zhen Ci Yan Jiu 2013;38(5):403-6, 410. PMID 24308189
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
Ryan W Y Lee MD
Dr. Lee of the John A Burns School of Medicine at the University of Hawaii has no relevant financial relationships to disclose.
See Profile
Editor
-
Ann Tilton MD
Dr. Tilton has received honorariums from Allergan and Ipsen as an educator, advisor, and consultant.
See Profile
Former Authors
- Geoffrey Miller MD
- Michael V Johnston MD†
- Teresa G Matejovsky
- Alexander H Hoon Jr MD MPH
Patient Profile
- Age range of presentation
-
- 0 to 2 years of age
- Sex preponderance
-
- male=female
- Heredity
-
- Heredity may be a factor
- Population groups selectively affected
-
- none selectively affected
- Occupation groups selectively affected
-
- none selectively affected
ICD & OMIM codes
- ICD-10
-
- Cerebral palsy: G80
- ICD-11
-
- Spastic cerebral palsy: 8D20
- Dyskinetic cerebral palsy: 8D21
- Ataxic cerebral palsy: 8D22
- Worster-Drought syndrome: 8D23
- Other specified cerebral palsy: 8D2Y
- Cerebral palsy, unspecified: 8D2Z
- OMIM
-
- Cerebral palsy, symmetric spastic, autosomal recessive: #603513
- Cerebral palsy, ataxic, autosomal recessive: %605388
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Neurogenetic Disorders
Wilson disease
Oct. 23, 2024
-
Infectious Disorders
Zika virus: neurologic complications
Oct. 08, 2024
-
Neuro-Oncology
Anti-LGI1 encephalitis
Oct. 03, 2024
-
General Child Neurology
Cerebral edema in childhood
Sep. 29, 2024
-
Sleep Disorders
Fatal familial insomnia
Sep. 25, 2024
-
Neuro-Oncology
CNS germinoma
Sep. 25, 2024
-
Developmental Malformations
Vein of Galen malformations
Sep. 22, 2024